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The tight glycaemic control required to attenuate chronic complications in type 1 diabetes 
mellitus often requires numerous daily injections of bolus insulin. Typically insulin is 
administered by subcutaneous needle injection, insulin pen and catheters connected to insulin 
pumps. The routine multiple sc injections of insulin cause discomfort resulting in non-
compliance, a major factor negating the quality of life of diabetic patients. Studies suggest that 
the bolus insulin injections are associated with hyperinsulinaemia, insulin resistance, glucose 
intolerance, weight gain and accelerated development of cardiovascular complications. These 
challenges of needle phobia and stress have encouraged investigations of possible administration 
routes of insulin delivery such as oral, nasal, buccal, pulmonary, rectal, ocular and transdermal 
systems. The skin has increasingly become a route of the delivery of drugs with a range of 
compounds generating a great deal of interest in this area of research. Studies in our laboratory 
are concerned with developing optional insulin delivery routes based on amidated pectin 
hydrogel matrix gel. Investigations described in this thesis were mainly designed to establish 
whether pectin insulin (PI)-containing dermal patches of different insulin concentrations sustain 
controlled release of insulin into the bloodstream of streptozotocin (STZ)-induced diabetic rats 
with concomitant alleviation of diabetic symptoms in target tissues, most importantly, muscle 
and liver. This study also focused on the hypoglycaemic effects of oleanolic acid (OA) which has 
been shown to significantly reduce blood glucose concentrations in both non-diabetic and 
diabetic rats when administered orally. OA does not dissolve easily in water hence we assessed 
the hypoglycaemic effects of OA via the transdermal route. 
 
Materials and methods 
Oral glucose test (OGT) responses to application of dermal patches containing different insulin 
concentrations were evaluated in separate groups of STZ-induced diabetic rats according to the 
method described previously by Musabayane et al., with slight modifications (Musabayane et al., 
2007). Similarly, OGT responses to application of dermal patches containing different OA 
concentrations were also evaluated. Groups of STZ-induced diabetic rats were fasted overnight 
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(18 h), followed by measuring blood glucose (time 0). The animals were given a glucose load of 
0.86 g/kg and then the patches were applied on the shaved skin on the dorsal region of the 
animals.  OGT responses to PI dermal matrix patches (2.47, 3.99, 9.57 and 16.80 µg/kg) 
prepared by dissolving pectin/insulin in deionised water and solidified with CaCl2 were 
monitored. Likewise, OGT responses to OA-containing dermal matrix patches (21, 42 and 84 
mg/kg) were also monitored. Short-term (5 weeks) metabolic effects were evaluated in separate 
groups of non-diabetic and STZ-induced diabetic rats housed individually in Makrolon 
polycarbonate metabolic cages (Tecniplats, Labotec, South Africa) and were allowed water ad 
libitum and daily given 30 g standard rat chow (Meadow Feeds, Pietermaritzburg, South Africa). 
These animals were treated thrice daily with dermal matrix patches 8 hours apart. Rats treated 
with drug-free pectin and insulin (175 µg/kg, sc.) acted as negative and positive controls, 
respectively. Blood, liver, gastrocnemius muscle, pancreas and skin were collected for 
measurements of selected biochemical parameters after the experimental period. Plasma insulin 
concentrations were measured from blood samples collected after 6 hours (acute) and after 5 
weeks (chronic) of treatment. 
 
Results 
Neither inflammation nor necrosis was detected in the skin of the rats after five weeks of daily 
treatment with PI-containing dermal patches. The density of phosphorylated IRS in skin tissues 
determined by immunohistochemical staining showed widespread localisation of IRS in cell 
bodies of the dermis, collagen and subcutaneous layer following treatment with PI-containing 
dermal patches. OGT responses and the area under the glucose curve (AUCglucose 0-360min) of 
untreated STZ-induced diabetic rats remained significantly elevated in comparison to the non-
diabetic control rats. Topical application of PI-containing dermal patches on the skin of STZ-
induced diabetic rats at various doses showed a statistically significant decrease in blood glucose 
and AUCglucose 0-360min at the end of the 6h experimental period by comparison to respective 
control rats. However, there was no dose-dependent effect on the magnitude of blood glucose 
lowering induced by PI-containing dermal patches. The blood glucose-lowering effects evoked 
by PI-containing dermal patches were similar to those of the standard drug (sc. insulin). 
Treatment of STZ-induced diabetic rats with OA-containing dermal patches at various doses 
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induced similar effects on the skin, IRS and blood glucose concentrations. Similar trends were 
observed chronically. Plasma insulin concentrations of untreated STZ-induced diabetic rats were 
significantly low compared with control non-diabetic rats. All PI treatments elevated plasma 
insulin concentrations of diabetic rats after the 6 h period but, the levels induced by low doses 
(2.47 and 3.99 µg/kg) were smaller than those caused by high doses (9.57 and 16.80 µg/kg). 
However, these effects on plasma insulin concentrations were comparable to those of sc insulin 
treated animals. Similarly, 5-week treatment with PI-containing dermal patches elevated plasma 
insulin concentrations although dose-dependent effects were not observed. Interestingly, the sc 
treated group remained low within levels that were comparable to those of the untreated STZ-
induced diabetic group. On the other hand, the plasma insulin concentrations of all OA treated 
groups remained significantly low at the end of the 6 h and 5-week experimental period in 
comparison to the non-diabetic control. There was no change in plasma insulin concentrations of 
STZ-induced diabetic rats following acute and short-term daily treatment with OA-containing 
dermal patches. Untreated STZ-induced diabetic rats exhibited significant depletion of glycogen 
and the expressions of glucose transporter-4 (GLUT-4) and glycogen synthase (GS) in liver and 
muscle tissues at the end of the 5-week study by comparison to non-diabetic rats at the 
corresponding time periods.  Treatment with the PI matrix patch restored the glycogen levels and 
the expressions of GLUT-4 and GS to levels comparable to those of non-diabetic control animals 
and sc insulin. Moreover, treatment of STZ-induced diabetic rats with PI-containing dermal 
patches decreased plasma creatinine concentrations and increased GFR without altering with the 
plasma urea concentrations. Treatment of STZ-induced diabetic rats with OA-containing dermal 




Dermal patches delivered relevant amounts of pharmacologically active insulin and OA as 
evidenced by blood glucose lowering effects in STZ-induced diabetic rats. PI and OA dermal 
matrix patches will be easy to use and will not require elaborative devices to prevent drug 
leakage as in solution formulations. The findings are of considerable importance because this 
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would free diabetic patients from daily bolus injections of insulin. Pectin has been used as a 
carrier of a wide variety of biologically active agents, for sustained release applications and 
targeting drugs to the colon for either local treatment or systemic action (Krusteva et al., 1990; 
Musabayane et al., 2000).  The non-invasive PI- and OA-containing dermal patches may offer 
minimally invasive drug delivery in clinical applications to perhaps improve drug bioavailability 
and patient compliance. Interestingly, comparisons of the effects of PI and OA dermal patches of 
different insulin and OA concentrations on blood glucose lowering could not be separated 
statistically. The failure to observe these effects cannot be explained by the present study, but 
may be attributed to the narrow range of the doses used in the present study. These effects were 
also not statistically different from those of sc insulin. In summary, the ability of PI and OA-
containing dermal patches to reduce blood glucose with concomitant alleviation of symptoms 
associated with diabetes could be attributed to the ability of pectin to entrap and release drugs in 
a sustained and controlled manner. The PI- and OA-containing dermal hydrogel matrix patch 




The current study has demonstrated that the pectin hydrogel insulin and OA dermal patches have 
the potential to deliver insulin and OA across the skin and into the blood stream and lower blood 
glucose concentrations and alleviate some symptoms associated with diabetes.  
 
Recommendations 
The limitations of the study include the absence of lipid profile and liver function assessment. In 
this regard, it is envisaged to utilize the obese Zucker diabetic rat model in future studies. 
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1.0.  Background 
The tight glycaemic control required by type 1 diabetes mellitus patients to attenuate chronic 
complications often requires numerous daily injections of bolus insulin. Typically insulin is 
administered by subcutaneous needle injection, insulin pen and catheters connected to insulin 
pumps. The routine multiple subcutaneous injections of insulin cause local discomfort resulting 
in non-compliance, a major factor negating the quality of life of type 1 diabetic patients.  
Previous studies suggest that the bolus insulin injections are associated with hyperinsulinaemia 
which has been associated with insulin resistance, glucose intolerance, weight gain and 
accelerated development of kidney and cardiovascular complications. These challenges including 
needle phobia and stress have encouraged investigations of alternative routes of insulin delivery 
such as oral, nasal, buccal, pulmonary, rectal, ocular and transdermal systems. The skin has 
increasingly become a route for the delivery of drugs with a range of compounds being 
considered for transdermal delivery generating a great deal of interest in this area of research. 
Transdermal insulin delivery route offers good patient compliance and controlled insulin release 
over time by avoiding possible degradation due to the gastrointestinal tract or first-pass liver 
effects. Despite these advantages, transdermal drug delivery is severely limited by the low 
permeability of skin caused mainly by stratum corneum, the skin’s outermost layer. Various 
techniques including iontophoresis, chemicals, ultrasound and electroporation have, however, 
been shown to enhance transdermal drug transport. Reports suggest that pectin (polygalacturonic 
acid) not only delivers drugs to the colonic region of the gastrointestinal tract, but also produces 
sustained release in vitro. More interestingly, our laboratory has succeeded in sustaining plasma 
insulin concentrations in diabetic rats using orally administered insulin-loaded amidated pectin 
hydrogel beads. The main purpose of the present study was to investigate whether topical 
application of amidated matrix pectin insulin (PI)-containing dermal patches can sustain 
controlled release of insulin into the bloodstream of streptozotocin (STZ)-induced diabetic rats 
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with concomitant alleviation of complications associated with diabetes in target tissues, most 
importantly, muscle and liver.  
 
This study also focused on the hypoglycaemic effects of transdermally administered oleanolic 
acid (3ß-hydroxy-olea-12-en-28-oic acid, OA) which has been shown to significantly reduce 
blood glucose concentrations in both non-diabetic and diabetic rats when delivered orally. 
Although the oral route of drug delivery proved to be successful, OA does not dissolve easily in 
water hence the need to assess the therapeutic efficacy of OA via the transdermal route. The 
success of the route of administration is measured by the ability to elicit effective and predictable 
lowering of blood glucose concentrations and alleviating of diabetic symptoms. In addition to 
reduced insulin responsiveness in muscle in diabetes, evidence has emphasized the critical role 
of hypoglycaemic agents in hepatic glucose homeostasis. Therefore, the studies described in this 
thesis also investigated whether transdermally delivered insulin and OA can influence some 
selected parameters such as glycogen synthesis, the expression of insulin-stimulated enzymes 
and facilitative glucose transporters in the livers and gastrocnemius muscles of STZ-induced 
diabetic rats. Chapter 1 describes the physiology of glucose homeostasis, diabetic associated 

















1.1.  General 
Glucose homeostasis is primarily maintained by the glycolytic and glycogenic pathways under 
normal conditions. The conversion of glucose into glycogen in the liver and muscle tissues 
results in the removal of glucose from the blood in the postprandial state. Furthermore, the 
maintenance of constant blood glucose levels is also brought about by glycogenesis between 
meals and gluconeogenesis in prolonged fasting. Metabolic disorders such as diabetes mellitus 
lead to interferences in the above mentioned pathways resulting in impaired glucose homeostasis 
(Daisy et al., 2010). This study investigated whether dermal patches containing insulin and OA 




1.2.  Glucose homeostasis  
Normal levels of blood glucose concentrations are maintained by a negative feedback 
mechanism that involves antagonistic metabolic hormones such as insulin and glucagon. 
However, hormones such as catecholamines, cortisol and growth hormone have also been shown 
to counter-regulate insulin actions. Insulin, the anabolic pancreatic β-cell hormone, decreases 
blood glucose concentrations if they exceed normal glycaemic levels whereas glucagon, the 
catabolic hormone, increases blood glucose concentrations to normal glycaemic levels (Obici et 
al., 2002). Glucose transport into the liver, muscle and adipose tissue leads to the synthesis of 
glycogen, proteins and lipids (Obici et al., 2002). However, glucose cannot permeate readily 
through the lipid bilayer that makes up the cell membranes of the above mentioned tissues. 
Therefore, transport carriers such as GLUT transporters are required for glucose transport 
(Medina and Gareth, 2002). This study investigated the effects of insulin and OA-containing 
dermal patches on the expression of insulin-stimulated glucose transporters in STZ-induced 







1.2.1.  Glucose transport  
Glucose transport into the cells is mediated by two distinct molecular families of cellular 
transporters namely the sodium-linked glucose transporters (SGLT) and the glucose transporters 
(GLUT) (Medina and Gareth, 2002). The GLUT transporters are intrinsic membrane proteins 
which differ in tissue-specific expression and response to metabolic and hormonal regulation. 
The GLUT transporters are sub-divided into 12 different isoforms, each with different affinities 
for glucose (Medina and Gareth, 2002). These GLUT transporters transport glucose by facilitated 
diffusion down a concentration gradient (Ali et al., 2002; Jung et al., 2007). Glucose transport 
into the cells can also be mediated by sodium-linked glucose transporters (SGLT) which are 
associated with the intestines and kidneys. They actively transport glucose against a glucose 
concentration gradient by making use of sodium co-transport as the main source of energy 
(Wood and Trayhurn, 2003; Jung et al., 2007). The translocation of glucose can also be due to 
muscle contraction which uses calcium release from the sarcoplasm reticulum during exercise 
due to autocrine- or paracrine activation of glucose transport (Pereira and Lancha Jr., 2004). 
 
Glucose entry in the liver is through the GLUT-2 transporters whereas glucose entry in the 
muscle and adipose tissue is through the GLUT-4 transporters (Daisy et al., 2010) (Figure 1). 
The GLUT-2 transporters are expressed in the liver whereas the GLUT-4 transporters are 
expressed in the muscle and adipose tissue (Daisy et al., 2010). Insulin secretion is triggered by 
the rise in blood glucose concentrations above normal levels (Sun et al., 2007). This then 
stimulates the insulin receptor (IR) which consists of two identical extracellular α-subunits and 
two transmembrane β-subunits that have tyrosine kinase activity (Jung et al., 2007; Daisy et al., 
2010). In response to increased blood glucose levels insulin is secreted by pancreatic β-cells 
(Murray et al. 2003). Insulin binds to the α-subunit and cause conformational change and 
stimulation of the receptor kinase activity via auto-phosphorylation of tyrosine residues in the β-
subunits (Jung et al., 2007). The activated IR kinase phosphorylates substrate proteins including 
the IRS family of proteins (Jung et al., 2007). The autophosphorylation of tyrosine kinase causes 
the activation of phosphoenositol-3-kinase (PI-3-K) which results to the translocation of the 
vesicle containing the GLUT-4 transporter to the membrane so that glucose can enter the cell 
(Shepherd et al., 1998; Rios, 2008; Daisy et al., 2010). Insulin plays an important role in 
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translocation of GLUT-4 from an intracellular pool to the plasma membrane of a muscle tissue. 
Lack of insulin, therefore, results in deprived cellular glucose uptake which is due to an 
inhibition of glucose transporter (Cushman and Wardzala, 1980). Defects in insulin secretion 
ultimately results in hyperglycaemia. This study therefore investigated the effects of the novel 
formulations on the expression of facilitative glucose transporters of liver and muscle tissues in 
STZ-induced diabetic rats. 
 
The entry of glucose into cells leads to a conversion of glucose to glucose-6-phosphate by 
glucokinase in the liver and hexokinase in the muscle (Vats et al., 2003). The phosphorylation of 
glucose by glucokinase in the liver promotes the synthesis of glycogen whilst phosphorylation of 
glucose in the β-cell leads to insulin release. Glucokinase has a high Km (low affinity) for 
glucose and is only found in the liver and pancreas. This enzyme is the main glucose 
phosphorylating enzyme in the hepatocytes, insulin and glucagon-secreting cells of the pancreas 
(Pal, 2009). Interestingly, glucokinase decreases the chances of hypoglycaemia since this 
enzyme does not affect insulin secretion at low glucose concentrations. Hexokinase on the other 
hand has a low Km (high affinity) for glucose and is found in the muscle. This enzyme can 
convert glucose to glucose-6-phosphate even if glucose concentrations are low (Pal, 2009). 
These enzymes, therefore, play key roles in the utilization of glucose by the cells.  
 
Glucose is firstly driven towards the glycolytic pathway to provide the body with ATP. Once the 
body’s energy needs are met, glycogen synthesis is initiated (Allouche et al., 2010). Glucose is 
converted to glucose-6-phosphate which is then converted to glucose-1-phosphate by 
phosphoglucomutase. The reaction catalysed by pyrophosphorylase leads to the conversion of 
glucose-1-phosphate to uridine diphosphate (UDP)-glucose which is acted upon by glycogen 
synthase to yield glycogen (Vats et al., 2003). Diabetes is, therefore, associated with alterations 
in glucose homeostasis such as the depletion in glycogen and glycogenic enzymes in liver and 
muscle tissues which lead to various biochemical complications that are detrimental to the health 
of diabetic patients. This study was designed to investigate whether topical application of insulin 
and OA-containing dermal patches can influence transporters and enzymes associated with 






Figure 1: A diagram showing the involvement of glucose transporters following insulin 
secretion and activation of the transduction pathways which ultimately leads to the conversion of 













1.3.  Classification of diabetes mellitus  
Diabetes mellitus is a chronic metabolic disorder characterised by hyperglycaemia due to the 
failure of insulin secretion by the pancreatic β cells (type 1), insulin resistance (type 2) and 
gestation  (Shivanand, 2010). Type 1 diabetes which accounts for about 10% of diabetic cases 
may be caused by autoimmune destruction of the pancreatic β-cells leading to insulin deficiency. 
Defects in insulin secretions ultimately results in hyperglycaemia. 
 
Type 2 diabetes accounts for about 90-95% of diabetes cases is caused by defects in the secretion 
of the pancreatic β cells and/or insulin resistance (Rolo and Palmeira, 2006). The specific 
aetiology is not clearly understood however, different risk factors are thought to be involved. 
These risk factors include genetic predisposition, lowered β-cell mass and obesity which results 
in to resistance. Due to resistance, insulin therapy is not usually effective. Research has shown 
that free fatty acids and adipokines in the adipose tissues may result in obesity which then leads 
to insulin resistance. To circumvent insulin resistance, β-pancreatic cells usually secrete more 
insulin and get exhausted in a long run (Association, 2005; Rolo and Palmeira, 2006). 
 
Gestational diabetes on the other hand is characterized by progressive insulin resistance which is 
observed from the beginning of the third trimester. This has been attributed to increased adipose 
tissues and steroid hormones (Buchanan et al., 2002; Buchanan et al., 2007). Gestational 
diabetes is characterised by β-pancreatic cells not being able to secrete sufficient insulin required 
during pregnancy (Pirkola, 2010). The insufficient insulin secretion in pregnancy results in 
similar causes observed in hyperglycaemia i.e. autoimmune, insulin resistance and monogenic 
cause (Buchanan et al., 2002; Buchanan et al., 2007). The pancreatic β-cells usually secrete more 
insulin to compensate for insulin resistance of pregnancy (Bhuchanan and Xiang, 2005). This 
type of diabetes results in elevated blood glucose concentrations that are seen in type 2 diabetes 
(Bhuchanan and Xiang, 2005).  
 
Reports indicate that more than 180 million people suffer from diabetes and this number is likely 
to be doubled by 2030 (WHO, 2006). Hyperglycaemia leads to alterations in carbohydrate, fat 
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and protein metabolism. Vats et al., reported that decreased carbohydrate, fat and protein 
metabolism reduces glycogen storage in the muscle and liver with concomitant reduction in the 
expression and activity of the glycogenic enzymes (glucokinase, hexokinase and glycogen 
synthase) (Vats et al., 2003). Therefore, there is a need to maintain normal blood glucose levels 
in order to avert biochemical complications that arise due to sustained hyperglycaemia. 
 
 
1.4.  Diabetic complications 
Diabetic complications triggered by hyperglycaemia arise from a wide range of metabolic 
pathways such as, the polyol pathway, advanced glycation end-products (AGEs), hexosamine 
pathway and protein kinase C activation (PKC). These metabolic pathways are discussed in the 
sections below. 
 
1.4.1.  Polyol pathway 
Hyperglycaemia in diabetes increase the polyol pathway flux since the excess glucose cannot be 
driven to the glycolytic pathway for metabolism. This process leads to an increase in the 
enzymatic conversion of glucose to sorbitol by aldolase reductase with concomitant decrease in 
nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) (Miwa et al., 2003). A 
decrease in NADPH results in a reduction in glutathione since NADPH is responsible for the 
synthesis of this important antioxidant (Miwa et al., 2003; Nam et al., 2009). A decrease in 
glutathione increases the risk of oxidative damage due to the loss of antioxidant reducing 
equivalents. Therefore, diabetic patients may be associated with severe cellular oxidative damage 
(Rolo and Palmeira, 2006). The osmotically active sorbitol causes osmotic stress in tissues such 
as the kidney, brain and retina. Sorbitol is reduced to fructose by sorbitol dehydrogenase thus 
increasing the NADH/NAD
+







1.4.2.  Protein kinase C  
Chronic hyperglycaemia leads to an increase in diacylglycerol (DAG) content which activates 
PKC that plays a role in several diabetic complications. These diabetic complications include 
disruption of cardiovascular, retinal and renal tissues (Brownlee, 2005; Geraldes and King, 
2010). PKC activation results in elevated blood pressure by decreasing vasodilators such as nitric 
oxide and increasing vasoconstrictors such as angiotensin II and endothelin-1 (Virbeti, 2005). 
Transforming growth factor-β and plasminogen activator inhibitor-1 are also increased by PKC 
activation (Brownlee, 2004).  The activation of PKC further leads to defects in vasculature such 
as blood vessel constriction and tissue ischemia which are often observed in diabetic patients.  
 
 
1.4.3.  Advanced glycosylation end products (AGE’s) 
AGEs play a role in the pathogenesis of microvascular complications of diabetes. The non-
enzymatic glycosylation of proteins is stimulated in hyperglycaemia. Protein glycosylation 
results in the formation of Schiff bases where the aldehyde group of glucose covalently binds to 
the amine group of the protein thus forming Amadori products (Aronson, 2002; Rolo and 
Palmeira, 2006). Advanced glycation is initiated by the accumulation of the Amadori glycation 
products on the proteins (Rolo and Palmeira, 2006). The interaction of AGEs with mesangial 
cells, endothelial cells and podocytes leads to the receptor-mediated production of reactive 
oxygen species involved in oxidative damage (Wendt et al., 2003; Fukami et al., 2004). AGEs 
also damage the cells by  interacting with the extracellular particles thus causing irregularities in 
the signals transferred from the matrix to the cells (Rolo and Palmeira, 2006). AGEs have also 
been shown to diffuse out of the endothelial cell and modify circulating proteins such as albumin 
in the blood. The binding of the modified proteins to AGE receptors triggers the production of 
inflammatory cytokines and growth factors which result in vascular manifestations such as the 
rapidly progressive atherosclerosis associated with diabetes mellitus. The uncontrolled glucose 





1.4.4.  The hexosamine pathway 
A lack of glycaemic control results in high amounts of glucose accumulating within cells. This 
glucose is then used for the process of glycolysis. The activity of the rate limiting enzyme, 
glutamine fructose-6 phosphate amidotransferase (GFAT) in the hexosamine pathway allows for 
the diversion and conversion of the glycolysis metabolite, fructose-6-phosphate  to glucosamine-
6 phosphate and then to UDP N-acetyl glucosamine (Schleicher and Weigert, 2000; Brownlee, 
2001). The O-linked glycoproteins, proteoglycans and glycolipids are then formed due to the 
presence of the precursor UDP N-acetyl glucosamine. The N-acetyl glucosamine produced also 
disrupts gene expression of many intracellular proteins by being deposited in serine and 
threonine residues that are involved in transcription (Schleicher and Weigert, 2000). 
Furthermore, N-acetyl glucosamine can enhance the expression of transforming growth factor-β 
and plasminogen activator inhibitor-1 resulting in detrimental effects on the vasculature. 
 
In addition, the above mentioned complications arise from the chronic hyperglycaemia observed 
in diabetic cases which can also contribute to hyperosmolality and hyperketonaemia (Garau et 
al., 2003). In cases of hyperketonaemia, glucose uptake by the cells is decreased due to insulin 
deficiency and unregulated glucagon secretion from α-cells of the pancreas. Circulating glucagon 
stimulates the adipose tissue to release fatty acids stored in triglycerides to enter the circulation 
where they undergo fatty acid oxidation. This leads to an increase in fatty acid metabolism by the 
liver resulting in an increase in circulating ketone bodies (Murray et al., 2003). The 
hyperosmolality observed in diabetes is characterised due to osmotic diuresis secondary to 
sustained hyperglycaemia. This can be mediated by the conversion of excess glucose to sorbitol. 
This product is osmotically active and has the ability to attract water which is lost collectively 
with glucose and electrolytes in the urine (Rolo and Palmeira, 2006). These biochemical 
complications are observed in patients with disruptions in glucose metabolism which contributes 







1.5.  Macrovascular and microvascular complications 
Diabetes mellitus is associated with macrovascular and microvascular complications. 
Macrovascular complications include coronary heart disease, atherosclerosis and peripheral 
arterial disease. Microvascular complications result in retinopathy, neuropathy and nephropathy 
(Hudson et al., 2005). Since glucose transport into the retina, neurons and nephron is insulin-
independent, glucose transport into these cells cannot be regulated. This increases their 
susceptibility to excessive amounts of glucose within the cell. 
 
1.5.1.  Macrovascular complications  
 
 
1.5.2.  Arterial diseases and atherosclerosis 
Arterial disease is associated with hypertension and dyslipidaemia which lead to inflammation 
and impaired fibrinolysis (Vinik and Flemmer, 2002). This causes changes in the vasculature 
thus favouring the initiation of atherosclerosis. Atherosclerosis is mediated, in part, by the 
imbalance of vasodilators such as nitric oxide and vasoconstrictors such as endothelin-1 and 
angiotensin II. These factors together with oxidative stress contribute to the disruption of the 
endothelial barrier (Vinik and Flemmer, 2002). Atherogenic lipoproteins like very low density 
lipoproteins (VLDL), oxidized lipoprotein (oxLDL) and lipoprotein become entrapped to the 
endothelial barrier consequently stimulating inflammation by attracting monocytes and T-cells 
which bind to the arterial wall due to increased expression of adhesion molecules (Vinik and 
Flemmer, 2002; Charpentier et al., 2003). Migration of these immune cells into the sub 
endothelial space for differentiation leads to plaque formation. In hypertension, the incorporation 
of glucose in the haemoglobin of red blood cells (RBCs) alters the normal deformability of the 
RBCs leading to the occlusion of the vessels. In addition, proteins such as haptoglobulin that are 
synthesized in patients with diabetes can increase blood viscosity resulting in elevated blood 




The progression of macrovascular complications is elicited, in part, by glycation caused by the 
accumulation and interaction of AGEs (Negre-Salvayre et al., 2009). This also leads to the 
oxidation of low density lipoproteins (LDLs). The oxidised LDLs then accumulate in the arterial 
endothelial wall causing blockage of the artery. Atherosclerosis plaque formation can cause 
significant consequences associated with cardiovascular diseases (CVD) which result in 
morbidity and mortality in diabetic patients (Laing et al., 2003). 
 
 
1.5.3.  Microvascular complications  
Microvascular complications are most common in type 1 diabetes and they include retinopathy, 
neuropathy and nephropathy (Barker et al., 1993; Virbeti, 2005; Pal, 2009). 
 
1.5.4.  Diabetic retinopathy 
Retinopathy refers to the overgrowth of blood vessels which causes blindness by damaging the 
retina (Hudson et al., 2005). This microvascular complication can be classified as proliferative or 
non-proliferative. This microvascular complication can be classified into proliferative and non-
proliferative stages. The non-proliferative stage begins when glucose accumulates in the eyes 
and increases osmotic pressure within the eye. The increased levels of glucose lead to the 
accumulation of sorbitol which causes basement thickening, microaneurysm and pericycle loss 
(Miwa et al., 2003). The damage is further precipitated by the non-enzymatic glycation of 
proteins in the eye to form AGEs that progressively accumulate in the lens and retina.  
Interestingly, studies have reported that an increase in blood glucose is directly proportional to 
AGEs formed in the retinal capillaries and inversely proportional to the amount of the outermost 
layer of cells in the retina of diabetic rats (Donald and Fong, 2002). In addition, research has 
shown that the blood flow of the retina is altered by the thickening of the basement membrane 
subsequent to the activation of PKC (Park et al., 2000). This proliferative stage is associated with 
cellular damage, expression of matrix proteins (like collagen and fibronectin) and expression of 




1.5.5.  Diabetic nephropathy 
Diabetic nephropathy is the most common cause of end-stage renal disease (Parving et al., 2002; 
Molitch et al., 2003). This complication is implicated in morbidity and mortality in diabetes 
(Molitch et al., 2003). Diabetic nephropathy is caused by an interaction between extracellular 
matrix metabolic and haemodynamic factors within the glomerulus, secondary to increased blood 
glucose concentration (Gnudi et al., 2003). The metabolic factors incorporate increased 
formation of AGEs, polyols and activation of PKC whereas the haemodynamic factors 
incorporate systemic hypertension and the quality of the afferent and efferent arterioles (Cooper 
et al., 1998; Gnudi et al., 2003). This in turn leads to decreased kidney function, an increase in 
the expression of GLUT-1 and an increase in glucose uptake by mesangial cells (Virbeti, 2005). 
This complication is associated with glomerular basement membrane thickening, mesangial 
expansion, glomerular and tubular hypertrophy (Parving et al., 2002). The accumulating of 
AGEs give rise to glomerular basement membrane thickening due to the interaction with 
mesangial cells, endothelial cells and podocytes. Furthermore, the accumulation of AGEs also 
decrease glomerular filtration (Gnudi et al., 2003). 
 
In the early stages of diabetic nephropathy there is an increase in glomerular filtration rate due to 
the injury of the glomerulus. In addition, glomerular filtration rate is also increased when blood 
flow and vascular permeability is increased (Gnudi et al., 2003). These complications bring 
about changes in the kidney which include hypertrophy, tubular atrophy and decreases ion 
transport.  
 
In the late stages of diabetic nephropathy proteinuria contributes in precipitating renal failure. 
The injury of endothelia, mesangia and podocytes is the principal cause of increased filtration of 
proteins in tubular lumen (Sanchez-Lozada et al., 2004). This leads to a decrease in the number 
of functional nephrons which in turn increases glomerular capillary pressure. These events result 
in decreased sodium reabsorption. A complete destruction of post-glomerular capillaries results 
in renal injury (Molitch et al., 2003). Reports indicate that treatment with angiotensin converting 
enzyme inhibitors (ACEs) and angiotensin receptor blockers (ARBs) has the potential to 
decrease intraglomerular pressure and proteinuria (Thomson et al., 2008). Studies have also 
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reported that the oral administration of OA can improve renal function by increasing urinary Na
+ 
excretion, reducing plasma creatinine and elevating glomerular filtration rate in experimental 
diabetes (Mapanga et al., 2009; Madlala et al., 2012). This study therefore investigated the 
hypoglycaemic effects of this triterpene when delivered transdermally. 
 
1.5.6.  Diabetic neuropathy 
Diabetic neuropathy is associated with metabolic dysfunction of nerve fibres, auto-immune 
damage and deficiency of neurogrowth hormone factors (Pittenger and Vinik, 2003). This 
complication is usually characterised by a lack in wound healing. This results from decreased 
oxygen in tissues due to glycated haemoglobin and altered immune system. Reports indicate that 
this complication is associated with increased prevalence of ulceration and limb amputations 
(Thomson et al., 2008). The impaired nerve conduction velocity seen in diabetic neuropathy is in 
part due to the accumulation of sorbitol and fructose in the nerve cell where they cause protein 




-ATPase (Dobretsov et al., 2007). The dysfunction 
and loss of axons can also be due to oxidative stress stimulated by the activity of PKC. 
Furthermore, the blood supply to neurones may be impaired by vascular damage and endoneural 
hypoxia which causes capillary damage resulting to impaired axonal metabolism and nerve 
conduction (Oates, 2002). 
 
Medicinal plants such as Aloe vera have been used to reduce progression of diabetic neuropathy 
and has been shown to improve wound healing which is characterised by connective tissue 
abnormalities in diabetic patients (Chithra et al., 1998). There is a need for treatment that will 
confer preventive and anti-hyperglycaemic effects against diabetic complications. Conventional 
and herbal treatments have been widely used to combat diabetes and its complications. This is 








1.6.  Management 
Treatment of diabetes mellitus aims to lower the high blood glucose levels to normal glycaemic 
levels (Shivanand, 2010) and involves the use of anti-diabetic synthetic drugs such as 
sulphonylureas, biguanides, α-glucosidase inhibitors and thiazolidenediones (Oikinine and 
Mooradian, 2003) (Figure 2). Insulin, however, has remained the primary means of treating type 



















Figure 2: Diagram showing the drugs used in the management of diabetes.  These drugs include 
the subcutaneous injection of insulin as well as sulphonylureas, biguanides, α-glucosidase 
inhibitors and thiazolidenediones which increase insulin secretion, decrease hepatic 















Under normal conditions, the secretion of insulin is triggered by glucose concentration. Insulin 
and glucagon are involved in glucose homeostasis via the negative feedback mechanism (Sun et 
al., 2007). The signal transduction pathway described in glucose homeostasis section causes 
glucose to enter the pancreatic β-cell via glucose transporter 2 (GLUT-2). Glucose is then 
converted to glucose-6-phosphate which through a series of metabolic reactions results in the 
increase of citric acid cycle and electron transport (Pal, 2009). An increase in rate of citric acid 
cycle and rate of oxidative phosphorylation results in an increase in ATP: ADP ratio leaving 
fewer potassium ions on the inside than on the outside of the pancreatic β-cell. This causes the 
ATP-sensitive potassium channels to close thus leading to a change in the voltage of the 
depolarised membrane. This results in calcium influx through the voltage-gated calcium channel 
which stimulates the secretory vesicle to bind onto the membrane so that insulin can be released 
from the pancreatic β-cell to the circulation (Pal, 2009). In cases where insulin cannot be 
secreted into the circulation by the pancreatic β-cell, there is a need to administer anti-diabetic 
synthetic drugs with insulin-mimetic effects. These drugs are briefly described in the section 
below. 
 
1.6.1.  Sulphonylureas          
Sulphonylureas exert their hypoglycaemic effects primarily by increasing the release of insulin 
from residual functioning pancreatic β-cells. The mechanism of action is through the binding of 
sulphonylureas to the potassium channels which are activated by low ATP concentrations and 
inhibited by high concentrations of ATP (Evans  and Rushakoff, 2002). The opening of the KATP 
channels hyperpolarizes the cell whereas the inhibition of KATP channels causes membrane 
depolarization and an influx of calcium via voltage-dependant calcium channels on the β-cells 
membrane (Dileep and Memon, 2006). The release of insulin is then triggered by the increase in 
the intracytosolic calcium concentrations (Evans  and Rushakoff, 2002; Oikinine and Mooradian, 
2003). In addition, glucose is also known to indirectly inhibit these channels by increasing the 
levels of ATP (Evans  and Rushakoff, 2002). The hypoglycaemic effects triggered by direct 
stimulation of the pancreatic β-cells to enhance insulin secretion have also been reported in 




Sulphonylureas are associated with side effects such as weight gain, overstimulation of insulin 
by the pancreatic β-cells leading to hypoglycaemia and pancreatic β-cell exhaustion. 
 
 
1.6.2.  Biguanides 
The biguanides reduce hepatic gluconeogenesis and increase glucose uptake and utilization by 
the muscle (Oikinine and Mooradian, 2003). The mechanism of action is through the activation 
of AMP-activated protein kinase (AMPK) an enzyme which plays a major role in the stimulation 
of glucose uptake in the skeletal muscle (Musi and Goodyear, 2003). The pathway is activated in 
response to reduced cellular energy stores observed in diabetes mellitus cases. The biguanide, 
metformin, is therefore preferred in obese patients with insulin resistance since it reduces 
adiposity and possess anti-hypertensive and anti-lipidaemic properties (Oikinine and Mooradian, 
2003). 
 
1.6.3. Thiazolidinediones  
Like the biguanides, the class of thiazolidinediones (TZDs) exerts their effects on the liver and 
skeletal muscle where they decrease glucose blood levels by increasing the rate of conversion 
from glucose to glycogen (Dandona et al., 2008). Reports indicate that TZDs are potent agonists 
for the PPAR γ (Yki-Jarvinen, 2004). The activation of these receptors controls the transcription 
of insulin-responsive genes involved in the control of production, transport and utilization of 
glucose (Yki-Jarvinen, 2004). Thiazolidinediones, therefore, promote insulin sensitivity and 
glucose entry in skeletal muscle at the same time reducing fat synthesis (Oikinine and 
Mooradian, 2003). TZDs such as rosiglitazone and pioglitazone have been reported to reduce 
insulin resistance in monotherapy and in combination with metformin or sulphonylureas (Virbeti, 
2005). However, the anti-hyperglycaemic effects of TZDs are associated with undesirable effects 







1.6.4. α-Glucosidase inhibitors 
The class of α-glucosidase inhibitors targets the small intestines to inhibit the brush border 
enzymes from hydrolysing polysaccharides to monosaccharides. This is a competitive and 
reversible inhibition that delays polysaccharides hydrolysis to monosaccharaides that are much 
easier to absorb (Oikinine and Mooradian, 2003; Mahomoodally et al., 2004).  Alpha 
glucosidase inhibitors have been associated with flatulence because of the resultant accumulation 
of polysaccharides in the colon. The accumulation results in the fermentation process that form 
gas in the intestines subsequent to metabolism of the polysaccharides by colonic flora. 
 
The above mentioned drugs however, are not easily accessible to the general population in the 
developing countries due to socioeconomic reasons. Therefore, there is a need for alternative 
methods such as medicinal plants. The use of medicinal plants in the management of diabetes has 
sparked great interest in the scientific community. Examples of medicinal plants that have been 
shown to exert hypoglycaemic effects in India include Aleo barbadensis, Artemisia pallens, 
Azadirachta indica, and Morus alba (Drover et.al. 2002). Furthermore, there are also plants such 
as Trigonella foenum graecum L. (Fenugreek) that have been shown to exert hypoglycaemic 
effects mediated through the stimulation of an insulin signalling pathway. Syzygium aromaticum-
derived OA has been found to inhibit α-glucosidase which leads to a decrease in elevated 
postprandial blood glucose associated with diabetes mellitus (Khathi et al., 2013). The inhibition 
of α-glucosidase by OA causes an interruption in gastric digestion thus resulting to delayed 
carbohydrate absorption (Ali et al., 2002). Furthermore, OA treatment decreases the activity of 
intestinal glucose transporters and carbohydrate hydrolysing enzymes to prevent a rise in 
postprandial blood glucose, hence a potential drug for treatment of diabetes (Khathi et al., 2013). 
 
1.6.5. Traditional (indigenous/folk) medicine 
Herbal treatments have also been widely used as means of lowering blood glucose. Reports 
indicate that 80% of the world’s developing countries rely on plants for medical treatment (Vats 
et al., 2003). Plant extracts from Sclerocarya birrea [(A. Rich.) Hochst], Persea amricana Mill 
(Lauracea) [“Avocado”], Ficus thonningii, Syzygium cordatum and Syzygium aromaticum 
possess hypoglycaemic properties with concomitant increase of glycogen synthesis in 
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streptozotocin (STZ) diabetic rats (Musabayane et al., 2007; Gondwe et al., 2008; Mapanga et 
al., 2009). Research has shown that medicinal plants are able to restore depleted glycogen levels 
in diabetic patients to normalcy (Vats et al., 2003). The restoration is mediated in part by the 
increased activity of the key glycogenic enzymes (Ngubane et al., 2011). 
 
Studies indicate that medicinal plants contain bioactive compounds with hypoglycaemic 
properties. These bioactive compounds include hedergenin, tormentic, myrianthic, betulinic acid, 
monoric acid, corosolic acid, ursolic acid, maslinic acid and oleanolic acid (Raphael and Kuttan 
2003). Hederagenin, tormentic, myrianthic and ursolic acid have been shown to have insulin 
mimetic effects where as corosolic acid have been shown to exert hypoglycaemic effects through 
the inhibition glycogen phosphorylases thereby inhibiting the breakdown of glycogen (Wen et 
al., 2005). However, the triterpene oleanolic acid derived from Syzygium aromaticum (Figure 3) 






                
Figure 3: Diagram showing the leaves and the aromatic flower buds of a tree in the family 
Myrtaceae, Syzygium aromaticum. 
 
OA is a pentacyclic triterpene which has been found to have a variety of biological properties 
which include anti-HIV, anti-cancer, anti-diabetic and anti-inflammatory effects (Dzubak et al., 
2006). Previous studies reported that OA exerts hypoglycaemic effects by directly stimulating 
the pancreatic β-cells to enhance insulin secretion in isolated pancreatic β-cells (Teodoro et al., 
2008). However, the blood glucose lowering effects were observed in vitro as a result there is no 
evidence that the same mechanism is used in vivo. Recent in vitro studies have shown that OA 
decreases the absorption of glucose in the small intestine, decreases blood glucose and enhances 
other pathways that do not include insulin secretion (Khathi et al., 2013). Research in our 
laboratory has shown that the extract from Syzygium cordatum-derived OA lowers blood glucose 
in STZ-induced rats (Musabayane et al., 2005) and improves kidney function by increasing Na
+
 




Maslinic acid derived from Syzygium cordatum is another triterpene that has been shown to 
possess therapeutic effects such as anti-tumour (Di Carli et al., 2003), anti-HIV (Parra et al., 
2009), anti-oxidation (Allouche et al., 2010) and hypoglycaemic (Liu et al., 2007; Tang et al., 
2008; Mkhwanazi et al., 2012). MA has also been shown to possess hypoglycaemic effects by 
inhibiting glycogen phosphorylase (GP) which ultimately leads to the inhibition of hepatic 
glucose production (Wen et al., 2005). GP is the key enzyme that is abundant in the liver and is 
responsible for glycogen breakdown. The pharmacological inhibition of GP can be used as a 
therapeutic approach to circumvent abnormalities in glycogen metabolism (Wen et al., 2005; 
Chen et al., 2006). These bioactive agents have limited water solubility which affects their 
bioavailability when administered orally therefore there is a need to formulate alternative 
methods of administration. 
 
1.7.  Novel anti-diabetic drug delivery systems 
The conventional method used in the delivery of insulin into the systemic circulation is by 
subcutaneous injection of insulin (Mason et al., 2002). The subcutaneous method of drug 
administration is associated with multiple injections which may lead to local skin irritation and 
thus may contribute to patient non-compliance (Mason et al., 2002; Sonaje et al., 2010). Insulin 
administration via the subcutaneous route can result in hyperinsulinaemia due to the release of 
insulin in large amounts (Bastaki, 2005). Therefore, other delivery systems of insulin that would 
be more effective and more user-friendly have been considered. There are investigations on 
insulin formulations that can be administered via various routes in an effort to promote patient 
compliance as well as to mimic the physiological route of insulin with fewer side effects. These 
routes include nasal, intrapulmonary, buccal and intrauterine administration (Sintov and 
Wormser, 2007). However, reports have revealed that these routes of administration are 
associated with disadvantages such as poor absorption which results to loss of efficacy. 
 
Nasal administration has been another potential route for insulin delivery due to high 
vascularisation and large surface area of absorption in the nasal cavity (Callens et al., 2003; 
Kushwaha et al., 2011). However, the nasal route of administration has been associated with low 
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bioavailability of the drug due to the presence of proteolytic enzymes and the active mucociliary 
clearance mechanism which prevents prolonged contact of the drug with the mucosa (Kushwaha 
et al., 2011). In addition, nasal irritation, immunogenicity and increased susceptibility of the 
mucosa to viruses or mitogens have been the downfall associated with this route of insulin 
delivery (Callens et al., 2003). 
 
Pulmonary administration of insulin is another potential route for insulin delivery since the lungs 
provide a large highly vascularised absorption area (Martanto et al., 2004; Prausnitz and Langer, 
2008). However, breathing characteristics have a major influence on intrapulmonary absorption 
(Martanto et al., 2004; Prausnitz and Langer, 2008). Therefore, parameters influencing breathing 
such as asthma, lung diseases, exercise and smoking will have to be investigated to assess their 
influence on insulin absorption. Due to the wide variance associated with this route of insulin 
delivery, the pharmacokinetics of this technique are not yet fully understood. 
 
Oral delivery of insulin and absorption from the gastrointestinal tract into the portal circulation is 
another route of administration which mimics the normal physiological process and may 
therefore provide better control of glucose homeostasis. This oral route is the most convenient 
and desirable form of delivery for chronic therapy. Studies have attempted to deliver insulin 
orally but this was accompanied by problems encountered in the gastrointestinal tract. These 
problems lead to pre-systemic degradation and structural changes of this hormone. Insulin is a 
polypeptide that is precluded by proteolytic enzymatic degradation in the stomach and small 
intestine and can thus be associated with low bio-availability when delivered orally (Owens et 
al., 2003). Reports have indicated that the absorption of large hydrophilic peptides may be 
prevented by the gastrointestinal mucosa (Shaji and Patole, 2008; Boegh et al., 2013). Therefore, 
therapeutic insulin approaches have been developed to increase absorption of insulin in the 
gastrointestinal tract. These strategies include the use of permeation enhancers like bile salts and 
fatty acids which may be associated with enzyme inhibitors like aprotinin, liposomes, emulsions, 
mucobioadhesives and polymer-based delivery systems (Owens et al., 2003; Shaji and Patole, 
2008). These vehicles are degraded in the liver resulting in the release of insulin into the 
systemic circulation. Although the use of the above mentioned permeation enhancers proved to 
have partial success, further investigations have been attempted.  
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Insulin is degraded by trypsin, α-chymotrypsin, elastase and to a lesser extent, by brush-border 
membrane-bound enzymes in the small intestine (Hirsch et al., 2005). Insulin administration 
supplemented by enzyme inhibitors provides possible means to circumvent the degradation of 
drugs that are protein in nature. Studies have evaluated the use of enzyme inhibitors such as 
sodium glycocholate, camostat mesilate, bacitracin, soybean trypsin inhibitor and aprotinin to 
slow the rate of insulin degradation across the gastrointestinal tract (Hirsch et al., 2005). These 
enzyme inhibitors were found to be effective in different segments of the gastrointestinal tract. 
Sodium glycocholate, camostat mesilate and bacitracin exerted inhibitory effects in the large 
intestine by improving the bio-availability of insulin. However, none of these enzyme inhibitors 
were effective in the small intestine which might be attributed to various enzymes secreted in 
this segment (Hirsch et al., 2005). Due to the complications associated with insulin co-
administration with enzyme inhibitors, an ideal delivery system for oral administration of insulin 
is needed to protect the hormone from the harsh environments of the gastrointestinal tract and to 
allow the hormone to penetrate through the epithelium as an intact molecule (Sonaje et al., 
2010). Several approaches have attempted to overcome barriers to oral delivery of insulin to the 
upper colon. Schilling and Mitra suggested that the delivery to the mid-jejunum protects insulin 
from hydrolysis and that the release in dosage form is enhanced by intestinal microflora 
(Schilling and Mitra, 1990). In addition, studies have reported that when an azopolymer-coated 
drug reaches the large intestine, the indigenous microflora reduces the azo bonds, breaks the 
crosslinks and degrades the polymer film thereby releasing the drug into the lumen of the colon 
for local absorption (Schilling and Mitra, 1990). On the basis of developing an alternative mode 
of administration and reduce frequency of injection often used by diabetic patients, oral insulin-
loaded amidated pectin hydrogel beads were formulated (Musabayane et al., 2000). The oral 
insulin formulation led to sustained plasma insulin concentrations (Musabayane et al., 2000). 
The end result can be attributed to the use of amidated pectin hydrogel beads since pectin is able 
to protect the drug from pre-systemic degradation. 
 
Pectin (polygalacturonic acid) is a non-toxic, complex mixture of polysaccharides present in the 
cell wall of most plants with a wide range of applications in pharmaceutical formulations (Ridley 
et al., 2001; Tho et al., 2006). This polymer is commercially extracted from citrus peels and 
apple pomace under mildly acidic conditions (Sriamornsak, 2003). Pectin has been successfully 
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used in the food and beverage industry as a gelling agent and has gained increasing application in 
pharmaceutical and biotechnology industries (Sriamornsak, 2003). Pectin consists of mainly 
linearly connected α (1-4)-D-galacturonic acid residues which have carboxylic groups with the 
galacturonic acid residues usually methyl-esterified (Sriamornsak and Nunthanid, 1998; Matia-
Merino et al., 2004; Lofgren et al., 2006). Pectins in which the degree of esterification (DE) is 
above 50% are known as high methoxy (HM) and below 50% are regarded as low methoxy (LM) 
(Tho et al., 2006). High methoxylated pectin requires a pH within narrow range around 3.0 in 
order to form gels. These high methoxylated pectin gels are thermally reversible and frequently 
contain a dispersion agent such as dextrose to prevent lumping (Sriamornsak, 2003). Low 
methoxylated pectin produce gels independent of sugar content and are less sensitive to pH 
compared to high methoxyl pectin. Both forms of pectins have the ability to form gels and 
matrixes which have allowed them to gain acceptance as carrier polymers for sustained drug 
release (Sriamornsak and Nunthanid, 1998; Morrow et al., 2007). The ability of pectin to form 
gels depends on the molecular size and degree of esterification (DE). The ratio of esterified GalA 
groups to total GalA groups is referred to as the DE which plays a major role in the classification 
of pectins (Sriamornsak, 2006). The polygalacturonic acid chain is partly esterified with methyl 
groups and the free acid groups may be partly or fully neutralised with sodium, potassium or 
ammonium (Sriamornsak, 2003). The DE of pectin is dependent on the species, tissue and the 
maturity of the source of pectin (Sriamornsak, 2003). The rate of gelation of pectin depends on 
the degree of esterification where a higher DE causes rapid setting and LM-pectins depend on 
the presence of divalent cations such as calcium. The viscosity of pectin depends on the 
molecular weight, concentration of the preparation, the pH and presence of counter ions in the 
solution (Sriamornsak, 1998). The mechanism of LM-pectin gelation relies mainly on the ‘egg-
box’ model which involves the formation of junction zones created by the ordered, side-by-side 
associations of galacturonans (Grant et al., 1973). This egg box model has specific sequences of 
GalA monomer in parallel or adjacent chains that are linked intermolecularly through 
electrostatic and ionic bonding of carboxyl groups. In addition, amidation increases or improves 
the gelling ability of low methoxy pectin. May (1990) reported that amidated pectins require less 
calcium to gel and that this pectin is less susceptible to precipitation at high calcium 
concentrations (May, 1990). During gelation of amidated low methoxyl pectins, ionic interaction 
between galacturonic acid residues and hydrogen bonding between amidated galacturonic acid 
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residues aid the gelation of the pectin (Sriamornsak, 2002). These interactions result in the 
formation of a net-like cross-linked pectin molecule (Sriamornsak, 2002). The cross-linkages 
formed by ionic bonds between the carboxyls are also involved in the gelling of amidated pectins 
and form stronger bonds thus producing a brittle and less elastic matrix. This cross linking plays 
a critical role in the entrapment of drugs for transdermal delivery with the addition of the 
divalent cation, calcium, increasing the chances of the formation of cross-links.  Furthermore, 
Musabayane et al., revealed that pectin has potential applications for transdermal delivery of 
drugs in a study that investigated the suitability of amidated pectin matrix patch for transdermal 
chloroquine delivery in an effort to mask the bitter taste associated with oral administration 
(Musabayane et al., 2003). Pectin has been shown to delay drug release in the upper 
gastrointestinal tract thus possessing the ability to specifically deliver drugs to the colon (pH 
above 7.5). The colon is the segment of the large intestine where pectin is de-esterified, swells 
and becomes degraded hence the implication that insulin can be protected from the harsh 
environment of the upper GIT and delivered to the colon (Sriamornsak, 1998). Moreover, the 
digestion of pectin in insulin-loaded amidated pectin hydrogel beads by the intestinal flora that 
inhabit the colon results in the release of insulin in dosage form. Although the use of pectin as a 
vehicle in oral administration of insulin proved to be beneficial to diabetic patients by alleviating 
the pain caused by subcutaneous injections, transdermal delivery is another route that has been 
formulated to administer insulin. The transdermal route of administration has sparked great 
interest in the scientific community due to the use of a patch or ointment to deliver a substance 
through the skin (Benson, 2005). 
 
Transdermal delivery (delivery of a drug through the skin) has also been speculated to provide 
better compliance and controlled sustained release of insulin in comparison with subcutaneous 
and oral administration. A number of drugs have been successfully delivered using transdermal 
delivery system. For many years, people have been placing substances on the skin for treatment 
of various ailments (Prausnitz and Langer, 2008). However, 1979 was the year when the first 
patch was developed and approved for the transdermal delivery of drugs into the systemic 
circulation (Prausnitz and Langer, 2008). This patch allowed the entry of a drug called 
scopolamine, a drug used for the treatment of motion sickness, into the systemic circulation. 
Since then, the development of transdermal formulations increased and the research is ongoing 
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(Prausnitz and Langer, 2008). The success of a transdermal formulation lies on the structure of 
the matrix within the patch and should offer numerous advantages over the conventional route of 
administration (Burgess et al., 2005). The transdermal route of administration allows the drug to 
escape gastrointestinal degradation by eliminating the variables such as pH, food intake and 
gastro-intestinal motility. This route of drug delivery avoids inconvenient dosing schedules of 
multiple injections associated with conventional subcutaneous administration. Moreover, 
transdermal delivery circumvents possible infectious disease transmission when using 
hypodermic needles and avoids disposal challenges associated with these hypodermic injections 
(Prausnitz and Langer, 2008). The transdermal formulation also avoids the first-pass metabolism 
by the liver and requires lower initial concentration of the drug. This route of administration is 
associated with disadvantages such as the low skin permeability of the stratum corneum and skin 
irritation. Drug delivery across the skin offers a non-invasive, user-friendly alternative to 
conventional delivery of insulin because the skin has a relatively large and readily accessible 
surface area for drug absorption (Benson, 2005). Transdermal delivery of drugs has undergone 
three generations of development (Prausnitz and Langer, 2008). The first generation being the 
transdermal systems that are available at present. In this generation, the drugs used in the patches 
have a low molecular weight, are lipophilic and are very effective at low concentrations 
(Prausnitz and Langer, 2008). However, the limitation of transdermal drug delivery system is 
low skin permeability due to the stratum corneum which serves as the first line of defence 
against substances against external substances entering the body through the skin thus limiting 
the effectiveness of the drug (Prausnitz and Langer, 2008). The skin is the first line of defence 
therefore some substances do not penetrate through. Furthermore, molecules that are larger than 
500Da cannot penetrate the skin (Naik et al., 2000). The skin has protective and homeostatic 
roles and is regarded as an important barrier to any external substances (Mills and Cross, 2006). 
The skin is divided into an epidermis, dermis and subcutaneous connective tissue (Kanitakis, 
2002). Investigations have shown that the stratum corneum is the actual barrier to most 
substances that come into contact with the skin by providing mechanical protection to the 
underlying epidermis and invasion by foreign substances. The stratum corneum is a semi-
permeable barrier that protects the underlying tissues and is made up of keratin-filled 
corneocytes (18-21 hexagonal cells) that are linked by an intracellular lipid bilayer that adopts a 
bricks and mortar arrangement (Naik et al., 2000). Due to the lipid bilayer nature of the stratum 
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corneum, the drug penetrating through the skin must have hydrophilic or lipophilic properties. 
These properties will allow for intracellular diffusion of the hydrophilic drug through the 
corneocytes thus passing the lipid head region of the lipid bilayer. Similarly, the lipophilic 
molecules will diffuse through the lipid tails (Martanto et al., 2004; Prausnitz and Langer, 2008). 
Literature evidence has shown that the “bricks and mortar” arrangement of corneocytes has 
allowed for the convoluted intercellular diffusion of solute following topical application of drugs 
(Figure 4). This diffusion however can be limited by the binding of the drug to the corneocytes 
as well as by the viscosity of the intercellular pathway (Roberts et al., 2002). Conversely, 
diffusion of drugs via the transcellular pathway is questionable since the drug would have to 
repeatedly penetrate through the lipophilic and hydrophilic compartments as well as the 
impenetrable intracellular matrix of the corneocytes (Figure 4). Furthermore, appendages such as 
hair follicles and sweat glands play a major role in the transport of drugs through the skin barrier 
since they have openings that effectively bypass the stratum corneum to the underlying dermal 
structures (Mills and Cross, 2006) (Figure 4). Literature evidence states that the thickness of the 
stratum corneum varies across the different regions of the skin therefore influencing drug 
transport following topical application. The stratum corneum is thickest in the plantar and palmar 
regions and thinner in the postauricular, axillary, and scalp regions of the body (Mehta, 2004). 
Therefore, the site of patch application may be towards the thinner region since drug transport 
may be limited in the thicker regions of the body (Mehta, 2004). The activity of the drug 
however is based on the movement from the vehicle into and through the skin. This means that 
the drug should be soluble in both the vehicle and the skin (Mills and Cross, 2006). Blood flow 
in the upper dermis is another factor that affects drug transport by acting as a sink to remove 
solutes that have penetrated through the stratum corneum and interruption of this blood flow 
reduces clearance of solutes and lead to peripheral accumulation of the drug below the site of 







Figure 4: Diagram showing the intercellular, transcellular and transappendageal routes of drug 
transport across the stratum corneum of the skin  
 
 
The second generation makes use of enhancers to increase the permeability of the skin (Prausnitz 
and Langer, 2008). This allows for the delivery of larger molecular weight drugs, and does not 
place restrictions on the molecular properties of the drugs used (Prausnitz and Langer, 2008). 
Skin permeability can be increased by the use of various types of enhancement methods such as 
iontophoresis, non-cavitational ultrasound and chemical enhancers. However, the focus of this 
study was on the use of chemical enhancers for skin permeability of larger molecules. The 
enhancer which increases transport of drugs across the stratum corneum must not have 
detrimental effects such as toxicity, irritation and allergy on the underlying tissues of the skin. In 
addition, a chemical enhancer should not have any pharmacological activity within the body and 
should return the barrier properties of the skin to normal when removed (Pathan and Setty, 
2009). Chemical enhancers interact with some of the components of the skin and increase 
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fluidity in the intercellular lipids.  However, no material has been found to possess all of the 
above properties but some chemicals have several of the above attributes. Urea and its 
derivatives which include dimethyl sulphoxide (DMSO) have been shown to facilitate diffusion 
of solutes by compromising the skin’s protective barrier (Notman et al., 2007). Urea facilitates 
transdermal penetration of solutes by forming hydrophilic diffusion channels within the barrier 
and by also increasing hydration of the skin (Pathan and Setty, 2009). Dimethyl sulphoxide is the 
earliest and most potent penetration enhancer belonging to the category of sulphoxides. This 
permeation enhancer is a very strong aprotic solvent capable of hydrogen bonding with itself 
instead of water (Williams and Barry, 2004). DMSO uses multiple, complex mechanisms by 
altering with the stratum corneum’s keratin from alpha-helical to β-sheet conformation thus 
aiding in drug permeation (Barry, 2001; Williams and Barry, 2004). DMSO has been proposed 
to facilitate penetration by increasing lipid fluidity which results in disruption of ordered 
structure of the lipid chains (Notman et al., 2007). This chemical enhancer is able to interact with 
hydrophobic and hydrophilic portions found in the skin’s lipid bilayers. The structure of DMSO 
has both hydrophobic and hydrophilic ends allows for the increase of the skin’s permeability in 
order for the drug to penetrate through (Benson, 2005). The effect of DMSO is concentration-
dependent and 60% is needed for optimal enhancement efficacy. However, at this high 
concentration, DMSO can cause scaling, erythema, stinging and burning sensations by 
denaturing some of skin proteins (Pathan and Setty, 2009). There are several fatty acids that have 
also been used as penetration enhancers.  These fatty acids, amongst many others, include oleic 
acid and sodium oleate. Reports have shown that unsaturated fatty acids are much more effective 
in permeating the skin when compared to saturated fatty acids. This is due to the attachment of 
unsaturated alkyl chain lengths of around C18 to a polar head group (Williams and Barry, 2004). 
Oleic acid has been shown to enhance penetration of a number of drugs at very low 
concentrations by interacting with and modifying the lipid domains of the stratum corneum 
(Sintov et al., 1999). Oleic acid also forms pools that disrupt the lipid bilayer thus allowing for 
the permeation of hydrophilic drugs (Larrucea et al., 2001; Williams and Barry, 2004).   
 
 
The third generation of transdermal delivery is a relatively new generation, and allows stronger 
disruption of the stratum corneum (Prausnitz and Langer, 2008). Although stronger disruption 
30 
 
usually affects the underlying tissues, in this generation these tissues are protected, thereby 
allowing for more effective transdermal delivery (Prausnitz and Langer, 2008). Electrical 
enhancers can also be used to increase permeability of the skin. This includes electrical 
enhancers via iontophoresis by driving charged molecules into the skin by a small direct current 
(0.5 mA/cm
2
) applied between two electrodes in contact with the skin to drive a charged 
molecule through the stratum corneum barrier (Zakzewski et al., 1998; Karande et al., 2002; 
Mills and Cross, 2006). Electroporation is another way to enhance penetration by applying short 
electrical pulses (100-1000V/cm) to create transient aqueous pores in lipid bilayers thus allowing 
the drug to penetrate more easily (Karande et al., 2002). Ultrasonic enhancers and microneedles 
can also be used to enhance penetration (Mitragotri, 2000; Lee et al., 2004; Martanto et al., 
2004). Ultrasound assists transdermal drug delivery by creating low frequency energy waves (20 
kHz) which disturb the stratum corneum layer by cavitation barrier (Mitragotri and Kost, 2000; 
Mills and Cross, 2006). Research has shown that this disruption ultimately allows for the entry of 
macromolecules into the body. This property is not clearly understood but is envisaged to give 
hope for the development of improved treatment methods for various diseases. We made use of 
the second generation of transdermal delivery in this study where DMSO was used in 
combination with antioxidants and an antibiotic as our penetration concoction. 
 
Antioxidants are another class of potent penetration enhancers and these include eucalyptus oil 
and vitamin E. Eucalyptus oil is a multifunctional component which is frequently used as 
flavouring agent or expectorant (Shahi et al., 2000; Songkro, 2009). This oil possesses 
bactericidal, antifungal and permeation enhancing properties. Reports indicate that eucalyptus oil 
can improve drug permeation and also offer a better antimicrobial stability which ultimately 
leads to a better chemical stability within the skin (Shahi et al., 2000; Songkro, 2009). On the 
other hand, vitamin E has been previously used in our laboratory for transdermal drug delivery to 
prevent physiological damage to the skin. Vitamin E acts by intercalating within the lipid bilayer 
and distorts the gel phase lipids. This decreases the gel state of phospholipid membrane thus 
causing permeation (Thiele and Ekanayake-Mudiyanselage, 2007). Moreover, vitamin E 
possesses antioxidative properties which confer protection to the skin thus preventing skin 
damage. Purmycin contains erythromycin which is a macrolide antibiotic that inhibits bacterial 
protein synthesis by binding to the 50S ribosomal subunit (Farrer, 2010). Erythromycin has 
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bacteriostatic action, however, at higher doses this antibiotic has been found to have bactericidal 
effect against susceptible organisms. Purmycin is active against gram-positive bacteria and has 
been reported to aid in protection by exerting anti-inflammatory effects caused by 
microorganisms or pathogens that are sensitive to erythromycin (Farrer, 2010). 
 
 
1.8.  Basis of the present study 
Challenges around subcutaneous administration of insulin have led to the innovation of novel 
drug delivery systems which are more effective, affordable and provide compliance. Therefore, 
methods which can deliver sustained therapeutic insulin concentrations into the blood based on 
topical applications may be beneficial with glycaemic control. Therefore, methods which can 
deliver sustained therapeutic insulin concentrations into the blood may be beneficial with 
glycaemic control. Medicinal plants such as Syzygium aromaticum may also be beneficial in 
glycaemic control since they have been shown to possess ingredients with hypoglycaemic 
effects. We speculated that use of PI matrix patch formulation may provide a sustained 
controlled release of therapeutic insulin doses which reduces blood glucose concentrations with 
concomitant elevation of insulin concentrations. We also speculated that the sustained controlled 
release of insulin from the PI matrix patch will alleviate some of the symptoms associated with 
diabetes in the liver and muscle tissues. Similarly, we envisaged that the OA-containing pectin 
patch matrix will mimic the effects exerted by the PI matrix patch formulation.  
 
1.9. Hypothesis and aims 
The hypothesis of the study was that there will be a change in blood glucose concentration 
following application of the novel transdermal formulations of insulin and OA. Hence, the aim of 
this study was to investigate the effects of the novel transdermal formulations of insulin and OA 
on blood glucose concentration in the STZ-induced diabetic rats in an effort to establish whether 
they sustain controlled insulin or OA release into the bloodstream and control some selected 








2.0.  Drugs and Chemicals  
Drugs and chemicals were sourced as indicated:  
Insulin (NovoRapid Pen Refill, Novo Nordisk Pty Ltd, Sandton, South Africa);  
dimethyl sulphoxide, bicinchoninic acid (BCA) reagent, sodium dodecyl sulphate (SDS), 
glycerol, nitrocellulose membrane, Trizma base (tris), triton X-100 (Sigma-Aldrich, St Louis, 
Missouri, United States of America);  
vitamin E (PharmaNatura (Pty) Ltd, Johannesburg, South Africa); eucalyptus oil (Barrs 
Pharmaceutical Industries cc, Cape Town, South Africa);  
purmycin (Pharmacare Ltd, Johannesburg, South Africa);  
calcium chloride (CaCl2), glucose (C6H12O6), potassium hydroxide (KOH), sodium sulphate 
(Na2SO4), sodium hydroxide (NaOH), citric acid (C6H8O7.H2O), tri-sodium citrate 
(Na3C6H5O7.2H2O), di-sodium hydrogen orthophosphate dihydrate (Na2HPO4.2H2O), sodium 
dihydrogen orthophosphate dehydrate (NaH2PO4.H2O), silica gel, ethyl acetate (EA), 
dichloromethane (DCM), ethanol (C2H5OH), methanol (CH3OH), chloroform (CHCl3) and 
hydrogen peroxide (H2O2) (Merck chemicals (Pty) Ltd, Wadeville, Johannesburg , South Africa) 
and 
isofor inhalation anaesthetic (Safeline Pharmaceuticals (Pty) Ltd, Weltevredan Park, Rooderport, 




Amidated low-methoxyl pectin pectin with a degree of methoxylation (DM) of 23, degree of 
amidation (DE) of 24 was kindly donated by Dr Hans-Ulrich Endress of Herbstreith and Fox 
KG, Neuenburg, Germany (See certificate in appendix I). This type of pectin is less sensitive to 
pH compared to high methoxyl pectins and can form gels independent of sugar content. 
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2.2. Isolation, purification and structural elucidation of oleanolic acid (OA) 
OA extraction was performed in Professor Fanie R. Van Heerden’s Chemistry laboratory at 
UKZN Pietermaritzburg campus. The triterpenoid was isolated from Syzygium aromaticum 
[(Linnaeus) Merrill & Perry] [Myrtaceae] cloves using a standard protocol that has been 
previously validated in our laboratory with slight modifications (Somova et al., 2003; Mapanga 
et al., 2009; Musabayane et al., 2010; Madlala et al., 2012). Briefly, air-dried S. aromaticum 
flower buds (500 g) were soaked at room temperature twice at 24 h intervals in 1 L of 
dichloromethane (DCM) and in 720 mL of ethyl-acetate on each occasion. The filtrate was 
filtered using a 30 cm filter paper (Whatman, Maidstone, Kent, England) and concentrated in 
vacuo 60± 1 
0
C using a laboratory 4000 efficient rotary evaporator (Laboratory Consumables 
and Chemical Supplies, Cape Town, South Africa) to obtain DCM soluble (63 g) and ethyl 
acetate soluble (EAS, 85 g). The crude EAS containing mixtures of oleanolic/ursolic acid and 
methyl maslinate/methyl corosolate was subjected to further purification by silica gel 60 column 
chromatography with a hexane: ethyl acetate 9:1 to 8:2 solvent system. Eluates with similar thin 
layer chromatography profiles were combined and subjected to further chromatographic 
purification resulting in a yield of 2.5 – 3.0 g of OA per 10 g EAS extraction. Analysed data 
collected from fractions was compared with authentic OA values. This yielded OA was further 
purified by recrystallization from chloroform-methanol (1:1, v/v) and the structure was 




C Nuclear Magnetic Resonance (NMR) 
technique. Preliminary studies indicated that the hypoglycaemic effects of S. aromaticum-
isolated OA and commercial OA were similar and hence the plant-extracted OA was used in the 











2.3.  Patch preparation and dissolution studies 
 
2.3.1.  Insulin patch 
Amidated pectin hydrogel insulin (PI) matrix patches of different insulin concentrations were 
prepared using a previously described protocol by Musabayane et al. with slight modifications 
(Musabayane et al., 2003). Briefly, 4 g of amidated low methoxyl pectin with a DM of 23 and a 
DE of 24 was dissolved in 100 mL of deionized water and mixed with agitation using a mixer 
(Heidolph instruments GmbH & Co. KG, Schwabach, Germany) for 30 min. Subsequently, 
DMSO (3 mL, Sigma-Aldrich Chemical Company, Missouri, St Louis, USA), eucalyptus oil (1.5 
mL, Barrs Pharmaceutical Industries cc, Cape Town, South Africa), vitamin E (1.5 mL, Pharma 
Natura Pty Ltd, Johannesburg, South Africa) and purmycin (100 µL, Pharmacare Ltd, 
Johannesburg, South Africa) were added to the mixture and left to spin for another 30 min after 
which various amounts (11, 23, 46 and 94 µg) of insulin (NovoRapid Pen Refill, Novo Nordisk 
Pty Ltd, Sandton, Gauteng, South Africa) were added to separate beakers and mixed with 
agitation in water bath at 37
o
C for 15 min. Following this, aliquots (11 mL) were transferred to 
petri dishes with known diameter and 2% CaCl2 solution was added on top and left at room 
temperature for 10 min to allow for cross-linking and hence formation of the matrix patch. 
Theoretically, the patches contained 11, 23, 46 and 94 µg of insulin. Patches of the same size 
were cut out of the main hydrogel resulting in patches containing 0.74, 1.20, 2.87 and 5.04 µg of 
insulin, respectively which translated to a dosage of 2.47, 3.99, 9.57 and 16.80 µg/kg, 
respectively. 
 
2.3.2. OA patch 
Amidated pectin hydrogel matrix patches with specified pectin-OA were prepared as described 
in the preceding section except for slight modifications that involved liquefying OA. Briefly, OA 
was dissolved in 3 mL of DMSO in a separate beaker overnight. Subsequently, various amounts 
(200, 400, 800 mg) of the dissolved OA (3 mL) were added to separate beakers containing the 
transdermal patch concoction as described for insulin, but without DMSO and mixed with 
agitation in water bath at 37 
o
C for 15 min. Following this, aliquots (11 mL) were transferred to 
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petri dishes with known diameter and 2% CaCl2 solution was added on top and left at room 
temperature for 10 min to allow for cross-linking and hence formation of the matrix patch. 
Theoretically, the patches contained 5.24, 10.48 and 20.95 mg of OA which translated to dosages 
of 21, 42 and 84 mg/kg, respectively. 
 
2.3.3. Determination of insulin amounts in patches 
Amidated PI dermal patches with specified pectin/insulin (11, 23, 46 and 94 μg) were dissolved 
in Sorenson’s phosphate buffer (pH 7.2) to determine the amount of insulin that was 
incorporated into each patch. Insulin concentrations were measured by ultrasensitive rat insulin 
ELISA kit (DRG Instruments GmBH, Marburg, Germany). Briefly, patches with known mean 
surface area of 4.20 ± 1.53 cm
2
 (n=6) cut out of the main hydrogel contained 0.74, 1.20, 2.87 and 
5.04 μg of insulin, respectively which translated to a dosage of 2.47, 3.99, 9.57 and 16.80 μg/kg, 
respectively. 
 
2.3.4. Stability of PI-containing dermal patches 
To assess the stability of insulin-containing dermal patches, the recovery percentages of insulin 
with the original insulin were monitored over a period of two months. Briefly, the petri dishes 
with PI hydrogel matrix formulation were sealed using an adhesive hydrofilm (Hartman-Congo 
Inc, Rock Hill, South Carolina, USA) to control for patch hydration and placed in an air tight 
plastic container (Tupperware Southern Africa (Pty) Ltd, Dunkeld, Johannesburg, South Africa) 
and stored in the refrigerator at 4 
o
C. In order to ascertain the amount of insulin that was 
incorporated into the patches, insulin content was determined in patches of known areas every 
week. The patches were dissolved in Sorenson’s phosphate buffer (pH 7.2) and the recovery 
percentages of insulin were measured by ultrasensitive rat insulin ELISA kit (DRG Instruments 







Male Sprague-Dawley rats (250–300 g) bred at the Biomedical Research Unit, University of 
KwaZulu-Natal were used in this study. The animals were kept and maintained under standard 
laboratory conditions of constant temperature (22±2 °C), humidity (55±5%), 12 h day: 12 h night 
cycle, and allowed water ad libitum and daily given 30 g standard rat chow (Meadow Feeds, 
Pietermaritzburg, South Africa).  
 
2.5. Ethical consideration 
Ethical clearance was obtained from the University of KwaZulu-Natal’s Ethics committee 
(References 079/11/Animal, 033/12/Animal, 059/13/Animal and 034/14/Animal (See appendices 
II, III, IV and V). 
 
2.6. Diabetic animal model 
To generate type 1 diabetes mellitus animal model, male Sprague-Dawley rats were injected with 
single intraperitoneal injection of 60 mg/kg STZ (Sigma-Aldrich Chemical Company, Missouri, 
St Louis, USA) in freshly prepared 0.1 M citrate buffer (pH 6.3). The control group received the 
vehicle citrate buffer (0.3 mL) through the same route. Animals that exhibited glucosuria after 24 
h, tested by urine strips (Rapidmed Diagnostics, Sandton, South Africa) were considered 
diabetic. Seven days later, the blood glucose concentration of STZ-induced diabetic rats greater 
than 20 mmol/ L
 










2.7.  Study design 
The study was designed to establish the effects of insulin- or OA-containing dermal patches on 
selected metabolic parameters in experimental diabetes. The experimental protocol is 























Figure 5: Flow diagram showing the study design divided into two components, the pectin patch 
preparation studies and animal studies. The animals were divided into groups that investigated 

















induced diabetic rats 
Glucose homeostasis studies 






2.8.  Application of the hydrogel patch  
Rats were shaved on the dorsal region of neck 1-2 days prior to the application of pectin 
hydrogel matrix patches to avoid pruritus. Preliminary studies have shown that there is no 
difference in the effect of the patch when placed in any region of the rat. The dermal patches 
were secured in place with adhesive hydrofilm (Hartman-Congo Inc, Rock Hill, South Carolina, 
USA) and rat jackets (Braintree, Scientific, Inc, Braintree, Massachusetts, USA) which were 





Figure 6: Transdermal application of the pectin matrix patch on a smoothly shaved dorsal region 




2.9. Acute effects 
Oral glucose tolerance (OGT) responses were conducted to investigate the blood glucose 
lowering effects following application of PI or OA-containing dermal matrix patches. 
 
2.9.1. OGT responses 
OGT responses to application of PI-containing dermal patches of different insulin concentrations 
were evaluated in separate groups of STZ-induced diabetic rats according to the method 
described previously by Musabayane et al., with slight modifications (Musabayane et al., 2007). 
Briefly, separate groups of STZ-induced diabetic rats were fasted overnight (18 h), followed by 
measuring blood glucose (time 0). The animals were given an oral glucose load of 0.86 g/kg and 
then the patches were applied on the shaved skin on the dorsal region of the animals.  
Subsequently, OGT responses to topically applied insulin pectin (PI) hydrogel patches at various 
doses of insulin (2.47, 3.99, 9.57 and 16.80 μg/kg) were monitored. Rats sham treated with drug- 
free pectin hydrogel matrix patches and insulin (175 μg/kg, sc) served as control animals and 
positive control animals, respectively. Blood glucose was measured using a OneTouch select 
glucometer (Lifescan, Mosta, Malta, United Kingdom) at 15 minutes intervals for the first hour 
and then hourly for the subsequent 5 hours.  
 
OGT responses to topically applied pectin-OA hydrogel matrix patches at various doses of OA 
(21, 42 and 84 mg/kg) were monitored as described above where rats sham treated with drug free 
pectin hydrogel matrix patches and insulin (175 μg/kg, sc)  served as control animals and 









2.10.  Short-term studies 
The effects of treatment with PI dermal patches on glucose homeostasis were evaluated in 
separate groups of non-diabetic and STZ-induced diabetic rats to further elucidate the 
mechanisms induced by the patch formulation. The effects of short-term (5 weeks) insulin 
treatment were evaluated in separate groups of non-diabetic and STZ-induced diabetic rats 
housed individually in Makrolon polycarbonate metabolic cages (Tecniplats, Labotec, South 
Africa). Animals were allowed water ad libitum and daily given 30 g standard rat chow 
(Meadow Feeds, Pietermaritzburg, South Africa). The PI dermal patches containing various 
doses (3.99, 9.57, 16.80 μg/kg) were topically applied three times onto the shaved skin area on 
the back of the neck at 09h00 followed by the same dose at 17h00 and then 8h later (01h00).  
 
Similarly, the effects of treatment with OA-containing dermal patches on glucose homeostasis 
were evaluated in separate groups of non-diabetic and STZ-induced diabetic rats to compare with 
previously reported oral effects of OA which does not dissolve easily in water. The effects of 
short-term (5 weeks) OA treatment was evaluated in separate groups of non-diabetic and STZ-
induced diabetic rats housed individually in Makrolon polycarbonate metabolic cages 
(Tecniplats, Labotec, South Africa). Animals were allowed water ad libitum and daily given 30 g 
standard rat chow (Meadow Feeds, Pietermaritzburg, South Africa). The same dosing regime 
was followed for topical application of various doses of OA (21, 42 and 84 mg/kg) onto the 
shaved skin area on the back of the neck. 
 
Animals treated with drug-free pectin and sc insulin (175 μg/kg) acted as negative and positive 
controls, respectively. Weight changes and amounts of food and water consumed were measured 
gravimetrically (Mettler balance PC 180-insruments, Protea Laboratory Services, South Africa) 








2.10.1.  Pharmacokinetic studies 
Blood samples were collected by cardiac puncture into pre-cooled heparinized tubes after 6 h 
from separate parallel groups of STZ-induced diabetic rats prepared as for OGT responses for 
insulin determination. Samples were also collected from all groups of animals by cardiac 
puncture into individual pre-cooled heparinized containers at the end of the 5-week experimental 
treatment period for biochemical measurements.  
 
2.10.2.  Tissue sample harvesting 
All animals were sacrificed by exposing to isofor inhalation anaesthetic for 3 min via a gas 
anaesthetic chamber (100 mg/kg) at the end of the 5 week experimental period. Thereafter, livers 
and gastrocnemius muscles were removed, snap frozen in liquid nitrogen and stored in a 
BioUltra freezer (Snijers Scientific, Tilburg, Netherlands) at -70 °C until use. Tissue samples of 
the skin (site on the dorsal region of neck skin where the patches were applied) and pancreas 
were also harvested and fixed in 10% formalin to assess morphological changes by histological 
analyses. Blood was collected by cardiac puncture into individual pre-cooled heparinized 
containers and centrifuged for 15 min at 959 x G and 4 °C (Eppendorf International, Hamburg, 
Germany) at the end of the 5-week experimental period. Separated plasma samples were stored 
in a Bio Ultra freezer at -70 °C until assayed. The collected plasma samples were used for urea, 
creatinine and insulin determination. The liver and gastrocnemius muscle were analysed for 
glycogen and protein content. 
 
2.10.3.  Skin and pancreas histology 
The effects of dermal patches and subcutaneous insulin daily treatments of diabetic rats for 5 
weeks on skin and pancreas morphology were evaluated by histological analysis. The skin and 
pancreas tissue samples were fixed in 10% formalin solution, rehydrated in decreasing grades of 
ethanol (100%, 70% and 50% ethanol for 2 min each) and embedded in paraffin wax. The tissues 
were sectioned (3-5 µm thick) with a microm rotary microtome (Robert-Bosch-Straße, Walldorf, 
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Baden-Württemberg, Germany). Subsequently, the sections were stained with haematoxylin 
(Sigma-Aldrich, St. Louis, Missouri, USA) for 5 min at room temperature and were allowed to 
stand under tap water for 10 min and rinsed in de-ionised water. The tissue sections were then 
counterstained with eosin (Sigma-Aldrich, St. Louis, Missouri, USA) for 3 min, rinsed in de-
ionised water, dehydrated in increasing grades of ethanol (90% and 100% for 2 min each) and 
cleared in two changes of xylene. The coverslips were then mounted on the slides with permount 
and the processed sections were viewed and captured using Leica scanner SCN 400 (Leica 
Microsystem CMS, GmbH, Ernst-Leitz-Strasse, Wetzlar, Germany). 
 
2.10.4.  Skin permeation studies  
To establish whether insulin was transported across skin of STZ-induced diabetic rats following 
topical application of pectin insulin-containing dermal matrix patches, we monitored the density 
of phosphorylated insulin receptor substrates (IRS) in skin tissues by immunohistochemical 
staining.  Similarly, the density of phosphorylated IRS on the skin of STZ-induced diabetic rats 
following 5-week treatment with pectin OA-containing dermal matrix patches was also 
monitored.  
 
Rats sham treated with drug free pectin hydrogel matrix patches and insulin (175 µg/kg, sc) 
served as negative control and positive control animals, respectively. Skin samples were also 
harvested from non-diabetic control animals. Formalin and paraffin wax embedded skin tissues 
were sectioned as described in the preceding section and fixed onto pre-cleaned X-tra adhesive 
slides (Leica Biosystems Peterborough Limited, Peterborough, Berkshire, U.K.). The slides were 
dewaxed, rehydrated following a standard immunohistochemical protocol and washed twice with 
TTBS (20 mM Tris, 150 mM NaCl, KCl, 0.05% Tween-20) at 2 min interval. The sections were 
then blocked in 2% BSA for 30 min and the excess buffer was removed with fibre-free filter 
paper. Subsequently, the sections were incubated in primary antibody (mouse anti-insulin 
receptor, 1:500, Abcam, Cambridge, United Kingdom) diluted in 1% BSA for 30 min at room 
temperature. Thereafter, they were washed thrice as before with TTBS and incubated in 
peroxidase buffer (Sigma-Aldrich, St. Louis, Missouri, USA) for 10 min.  The specimens were 
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then washed as before and incubated in secondary antibody (Rabbit anti-mouse IgG 1:100, Bio-
Rad, Johannesburg, South Africa) for 20 min. The specimens were stained with 
diaminobenzidine (DAB, Bio-Rad, Johannesburg, South Africa) for 5 min in the dark and then 
drop-washed in tap water. Finally the slides were counter-stained with Gill’s Haematoxylin 
(Sigma-Aldrich, St. Louis, Missouri, USA) for 3-5 min and blued in tap water for 5 min. The 
sections were then dehydrated with increasing degrees of alcohol and cleared with xylene. The 
coverslips were mounted with permount and the slides were then scanned using Leica scanner 
SCN 400 (Leica Microsystem CMS, GmbH, Ernst-Leitz-Strasse, Wetzlar, Germany). 
 
 
2.11.  Laboratory measurements 
 
2.11.1.  Insulin 
The plasma insulin concentrations were measured by ultrasensitive rat insulin ELISA kit (DRG 
Instruments GmBH, Marburg, Germany) which consisted of a 96 well plate coated with mouse 
monoclonal anti-insulin, standards, enzyme conjugate, enzyme conjugate buffer, substrate 
3,3',5,5'-tetramethylbenzidine (TMB), wash buffer and a stop solution. The principle of the assay 
is a solid phase two-site immunoassay based on the direct sandwich technique in which two 
monoclonal antibodies are directed towards separate antigenic determinants on the insulin 
molecule. During the incubation period insulin in the sample reacts with peroxidase-conjugate 
anti-insulin antibodies bound to the microtitration well. The washing step removed the unbound 
enzyme labeled antibody thus leaving the bound conjugate to react with TMB. The reaction was 
stopped by adding acid to give a colorimetric endpoint which is read spetrophotometrically using 
a microplate reader (BMG Labtech GmbH, Ortenberg, Germany) at 450nm. Each determination 
was performed in duplicate for standards and test samples. A 25 µL of each insulin standard (0, 
3.40, 8.50, 25.50, 68.10 and 170.27 pmol/L) was added to anti-insulin wells and plasma samples 
(25 µL) were added to the remaining anti-insulin wells. Subsequently, the enzyme conjugate 
(100 µL) was added to standard and plasma samples wells. The plates were then incubated at 
room temperature on a plate shaker (Heidolph, Schwabach, Germany) for 2 hours. The reaction 
volume was discarded and 350 µL of the wash buffer was added into all wells. The washing step 
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was repeated five times. After the final wash, the plates were inverted firmly against absorbent 
paper to remove excess liquid in the plates. The substrate, TMB (200 µL) was then added to all 
wells and incubated for 15 min.  The reaction was stopped by adding 50 µL of stop solution to 
all wells and mixing for 5 seconds on a plate shaker. The absorbance was measured using 
Spectrostar Nano microplate reader (BMG Labtech GmbH, Ortenberg, Germany). A standard 
curve was constructed from the absorbance values of the known concentrations of the standards 
using the spline regression curve. Insulin concentrations of the unknown samples were 
extrapolated from the standard curve. The lower limit of detection was 1.74 pmol/L. The intra- 
and inter-assay analytical coefficients of variation ranged from 4.4 to 5.5% and from 4.7 to 8.9%, 
respectively. 
 
2.11.2.  Glycogen  
The glycogen concentration was determined as previously described by Khathi et al. (Khathi et 
al., 2013). Briefly, liver and muscle tissue samples (1–1.5 g) were homogenized in 2 mL of 30% 
KOH solution and digested at 100°C for 30 min and then cooled in ice-saturated sodium 
sulphate. The glycogen was precipitated with ethanol and then pelleted, washed, and dissolved in 
deionized water. Glycogen standards (10–2000 mg/ L) were also prepared using glycogen 
powder. The glycogen concentration was determined by the reaction with the anthrone reagent (2 
g anthrone/1 of 95% (v/v) H2SO4) after which absorbance was measured at 620 nm using a 
Novaspec II spectrophotometer (Biochrom Ltd., Cambridge, UK). 
 
2.11.3.  Creatinine and urea 
Urea, urinary and plasma creatinine concentrations were determined by ion activity using the 
Beckman Coulter (Synchron CX3 Clinical Systems, Fullerton, Carlifornia, USA). Creatinine 
estimation employed the reaction of creatinine and picric acid at alkaline pH to form a yellow-
orange complex, creatinine picrate. Urea estimation employed the hydrolytic degradation of urea 
in the presence of urease.  The methods used standard kits and reagents purchased from 
Beckman Coulter, Dublin, Ireland. Glomerular filtration rate (GFR), as assessed by creatinine 
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clearance (CCr) was calculated using the standard formulae from measurements of the plasma 
and urinary concentrations of creatinine and urine flow rate in the 5th week. 
C = U x V/P 
where U is the urinary concentration, V is the urine flow rate and P is the plasma concentration. 
GFR values were calculated using creatinine clearance (CCr). 
 
 
2.11.4.  MDA measurements 
Thiobarbituric acid reactive substances (TBARS) assay measures levels of malondialdehyde 
(MDA) which is the product of lipid peroxidation. MDA reacts with thiobarbituric acid to form a 
colored complex which can be measured spectrophotometrically. Tissues (50 mg) were 
homogenised in 500 µL of 0.2% phosphoric acid. The homogenate was centrifuged at 400xg for 
10 min. Thereafter, 400 L of the homogenate was supplemented with 400 L 2% phosphoric 
acid and then separated into two glass tubes, each receiving equal volumes of the solution. 
Subsequently, 200 µL of 7% phosphoric acid was added into both glass tubes followed by the 
addition of 400 µL of thiobarbaturic acid (TBA) / butylated hydroxytoluene (BHT) into one 
glass tube (sample test) and 400 µL of 3mM hydrochloric acid (HCl) into the second glass tube 
(blank). To ensure an acidic pH of 1.5, 200 µL of 1M HCl was added to sample and blank test 
tubes. Both solutions were heated at 100 
o
C for 15 min, and allowed to cool to room temperature. 
Butanol (1.5 mL) was added to the cooled solution; the sample was vortexed for 1 min to ensure 
rigorous mixing and allowed to settle until 2 phases could be distinguished. The butanol phase 
(top layer) was transferred to eppendorf tubes and centrifuged at 13200xg for 6 min. The samples 
were aliquoted into a 96-well microtitre plate in triplicate and the absorbance was read at 532 nm 
(reference λ 600 nm) using a Spectrostar Nano microplate reader (BMG Labtech GmbH, 
Ortenberg, Germany). The absorbances from these wavelengths were used to calculate the 
concentration of MDA using Beer’s Law. 
[𝑀𝐷𝐴] (𝑛𝑚𝑜𝑙 𝑔−1) =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒





2.11.5.  Superoxide dismutase (SOD) measurements 
In the presence of SOD, the working solution can be reduced into a dye which can be measured 
photometrically. SOD activity was assessed by measuring the dismutation of superoxide radicals 
generated by xanthine oxidase and hypoxanthine in a convenient 96 well format.  SOD activity 
was measured using the Biovision SOD Assay Kit according to manufacturers’ instructions 
(BioVision Research Products, Mountain View, California, USA). Rat skin tissues (50 mg) were 
homogenized in ice cold 0.1M Tris / HCl (pH 7.4) containing 0.5% Triton X-100, 5mM β-
mercaptoethanol (ME) and 0.1mg mL
-1 
phenylmethanesulfonylfluoride (PMSF). The tissue 
homogenate was centrifuged at 14000xg for 5 min at 4ºC. The supernatant obtained was added to 
each sample (20 µL) and blank 2 (20 µL) well, while blank 1 and blank 3 wells received 20 µL 
of H2O. Thereafter, 200 µL of working solution was added to each well. Subsequently, dilution 
buffer (20 µL) was added to each blank 2 and blank 3 well, while each sample and blank 1 well 
received enzyme working solution (20 µL). The solutions were mixed thoroughly before reading 
the plate. Inhibition activity of SOD was colorimetrically measured using a Spectrostar Nano 
microplate reader (BMG Labtech GmbH, Ortenberg, Germany) after a reaction period of 20 
minutes at 37 ºC.  
𝑆𝑂𝐷 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝑛𝑚𝑜𝑙 𝑚𝑖𝑛−1 𝑚𝐿−1) =  
(𝐴 𝑏𝑙𝑎𝑛𝑘 1 − 𝐴 𝑏𝑙𝑎𝑛𝑘 3)  −  (𝐴 𝑠𝑎𝑚𝑝𝑙𝑒 1 −  𝐴 𝑏𝑙𝑎𝑛𝑘 2)
(𝐴 𝑏𝑙𝑎𝑛𝑘 1 − 𝐴 𝑏𝑙𝑎𝑛𝑘 3)
 × 100 
Where A represent the absorbance readings 
 
 
2.11.6.  Glutathione peroxidase (GPx) measurements 
Glutathione peroxidase (GPx) is an antioxidant enzyme which reduces liquid hydroperoxides to 
their corresponding alcohols and hydrogen peroxide to water through the oxidation of reduced 
glutathione (GSH) to oxidized glutathione (GSSG). GPx activity was measured in rat skin tissues 
using the Biovision GPx Assay Kit according to manufacturers’ instructions (BioVision 
Research Products, Mountain View, California, USA). The tissues (50 mg) were homogenized 
on ice in cold assay buffer (0.2 mL) and subsequently centrifuged at 10000xg for 15 min at 4 
o
C. 
The resultant supernatant (100 µL) was loaded into a 96-well plate in duplicate. The NADPH 
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standard curve was prepared by diluting the 1mM NADPH standard through a series of 
concentrations (0, 20, 40, 60, 80, 100 nmol per well). The optical density (OD) of the standards 
was measured at 340nm using a Spectrostar Nano microplate reader (BMG Labtech GmbH, 
Ortenberg, Germany) and the standard curve was constructed from the values obtained. A 
reaction mix (90 µL) containing assay buffer, NADPH, glutathione reductase and GSH was 
added into each sample well, mixed thoroughly and incubated for 15 min at room temperature. 
The OD was then measured (340nm) followed by the addition of cumene hydroperoxide (10 µL) 
and measurement of OD and another reading following a 5 min incubation in the dark (25 
o
C). 
The ODs from these wavelengths were used to calculate the concentration of GPx activity. 
𝐺𝑃𝑥 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝑛𝑚𝑜𝑙 𝑚𝑖𝑛−1𝑚𝐿−1) =  
(𝐵 −  𝐵0)
(𝑇2 −  𝑇1)  ×  𝑉
 × 𝑠𝑎𝑚𝑝𝑙𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 
Where: B - NADPH amount that was decreased between T1 (time of first reading) and T2 (time 
of second reading), B° - background change without cumene hydroperoxide between T1 and T2, 
V- pre-treated sample volume added into the reaction well 
 
 
2.11.7.  Glycogen synthase and GLUT-4 measurements 
To further elucidate the effects of insulin-containing dermal patches on the expressions of 
GLUT-4 and glycogen synthase (GS) in gastrocnemius muscle and liver tissues, respectively 
harvested after 5 weeks of treatment were analyzed using western blotting.  Tissue samples (0.1 
g) were homogenized on ice in isolation buffer (0.5mM Na2EDTA, 0.1 M KH2PO4, 0.1 mM 
dithiothreitol, 0.25 M sucrose) and then centrifuged at 400 x g for 10 min (4 
°
C). The protein 
content was quantified using the Lowry  method (Lowry et al., 1951) where BSA was used as 
standards (0-1 mg/mL). Samples were diluted using 0.1 N of sodium hydroxide to a final volume 
of 0.5 ml. Subsequently, 5 ml of alkaline reagent (4% sodium carbonate in 0.1 N of sodium 
hydroxide and 4% copper sulphate in 8% of sodium potassium tartrate) was added to the tubes 
containing samples. The mixture was then incubated at 40°C for 15 min and allowed to cool at 
room temperature. Then 0.5 ml of Folin Ciocalteu reagent diluted 1:2 with de-ionised water was 
added to the mixture and the tubes were left standing at room temperature for 30 min. The 
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absorbance in each sample was then read at 600 nm. The samples were all standardized to one 
concentration (1 mg/ mL).  
 
The standardized proteins were then denatured by boiling in laemmli sample buffer (0.5 M Tris-
HCl, glycerol, 10% sodium dodecyl sulfate (SDS), 2-mercaptoethanol, 1% bromophenol blue) 
for 5 min. The denatured proteins (25 µL) were loaded on prepared resolving (10%) and stacking 
(4%) polyacrylamide gels along with molecular weight marker (5 µL). The gel was 
electrophoresed for 1 h at 150 V in electrode (running) buffer (Trisbase, glycine, SDS), pH 8.3). 
Following electrophoresis, the resolved proteins were electro-transferred to an equilibrated 
polyvinylidene difluoride (PVDF) membrane for 1 h in transfer buffer (192 mM glycine, 25 mM 
Tris, 10% methanol). After transfer, the membrane was blocked with 5% non-fat dry milk in 
Tris-buffered saline with 0.1% Tween 20 (TTBS) (20 mM Tris, 150 mM NaCl, KCl, 0.05% 
Tween-20). The membrane was then immuno-probed with antibodies-GS and GLUT4 (1:1 000 
in 1% BSA, Neogen, USA) for 1 h at room temperature. The PVDF membrane was then 
subjected to 5 washes (10 min each with gentle agitation) in TTBS.  Following which, the 
membrane was incubated in horse radish peroxidase (HRP)-conjugated secondary antibody 
(rabbit anti-mouse 1:10 000; Bio-Rad) for 1 h at room temperature. After further washing, 
antigen-antibody complexes were detected by chemiluminescence using the Immune-star HRP 
substrate kit (Bio-Rad, Johannesburg, South Africa).  Chemiluminescent signals were detected 
with the Chemi-doc XRS gel documentation system and analysed using the quantity one 
software (Bio-Rad, Johannesburg, South Africa). Band intensity analysis was conducted on the 











2.12. Statistical analysis 
All data were expressed as means ± standard error of means (S.E.M.). The AUC0-360min values 
were calculated using blood glucose concentrations following topical application of PI matrix 
patches as well as OA-containing dermal patches. Statistical comparison of the differences 
between the control means and experimental groups was performed with GraphPad InStat 
Software (version 5.00, GraphPad Software, San Diego, California, USA), using one-way 
analysis of variance (ANOVA), followed by Tukey-Kramer multiple comparison test. A value of 





























3.0. Structural elucidation of OA 
 




C-NMR spectra of hydrogen and carbon atoms in the OA molecule. Following recrystallization 
with chloroform-methanol, the spectroscopic data was given as follows:  
1
HNMR CDCl3 δ, 0.73, 0.75, 0.88, 0.89, 0.90, 0.96, 1.11 (each 3H, s), 2.84 (1H, dd, J = 10.36), 
3.22 (
1
H, dd, J = 4.56, 5.26 (
1
H, t, J = 3.76);  
13
C NMR (CDCl3) : δ 183.5, 143.6, 122.7, 79.2, 55.4, 47.8, 46.8, 46.1, 41.8, 41.2, 39.5, 38.9, 
38.6, 38.3, 34.0, 33.3, 32.8, 32.7, 31.6, 28.4, 27.9, 27.4, 26.2, 23.8, 23.7, 23.1, 18.5, 17.4, 15.8, 
15.5.  
The two carbon signals at 143.6 and 122.7 ppm correspond to the carbon-carbon olefenic double 
bond at position 12 and 13 which is peculiar to the triterpenoids (Mahato and Kundu; 1994). 


























Figure 7: Syzygium aromaticum-derived OA 
1
H (A) and 
13
C- NMR (B) spectroscopic spectra. 















C-NMR (A) and OA with International Union 










3.1. Dissolution studies 
 
3.1.1. Percentage loading efficiency and stability of PI-containing dermal patches 
To determine the amount of insulin loaded in the pectin hydrogel matrix formulation and 
stability of PI patches, dissolution studies were conducted on freshly prepared insulin patches. 
Dissolution studies were also conducted on freshly prepared, a month and two months old 
insulin-containing dermal patches to assess the stability in the pectin hydrogel matrix 
formulation.  Table 1 shows the amount of insulin in PI patches. The theoretical amount of 
insulin in each patch was calculated from the known amount of insulin added to petri dishes 
during patch preparation and the area (4.20 ± 1.53 cm
2
) of the patches cut out of the petri dishes. 
The insulin incorporation in each patch ranged from 76 % to 94%. 
 
There was no significant difference in the amount of insulin incorporated in the PI hydrogel 
matrix patch over 2 month storage (75-80%) compared to the initial concentration thus indicating 

















Table 1: Insulin-loading in pectin hydrogel matrices, loading-efficiencies and stability of PI 
matrix patches: Data are expressed as mean ± SEM, n=6 in each group.  
 















0 11.72 11.01 ± 0.97 94 4.20 ± 1.53 0.74 ± 0.05 2.47  
0 23.43 17.81 ± 0.07 76 4.20 ± 1.53 1.20 ± 0.01 3.99 




93.70 74.98 ± 0.58 
70.28 ± 0.26 




4.20 ± 1.53 5.04 ± 0.01 
4.72 ± 0.09 


















3.2. Acute effects 
 
3.2.1. OGT responses 
OGT responses studies were carried out to investigate the effects of PI-containing dermal 
patches on blood glucose concentrations in STZ-induced diabetic rats. OGT responses of groups 
and the area under the glucose curve (AUCglucose 0-360min) of STZ-induced diabetic rats topically 
applied with PI-containing dermal hydrogel patches on the skin at various doses are shown in 
Figure 9. As can be seen in Figure 9, the blood glucose concentration of untreated STZ-induced 
diabetic rats increased to a peak after 15 min of glucose load and remained elevated until the end 
of the 6 h experimental period. Similarly, the blood glucose concentration of all PI treated STZ-
induced diabetic rats peaked to values above baseline after 15 min of glucose load. This was 
followed by a decrease in blood glucose concentrations which reached statistical significance as 
from the first hour to the end of the experiment in comparison to respective control animals. 
However, there was no dose-dependent effect on blood glucose-lowering effects of various doses 
of PI-containing dermal hydrogel matrix patches. In addition, the blood glucose AUC0-360min was 
smaller in animals treated with PI-containing dermal hydrogel patch matrices compared with 
respective untreated STZ-induced diabetic rats.  
 
Similarly, OGT response studies were also carried out to investigate the effects of OA-containing 
dermal patches on blood glucose concentrations in STZ-induced diabetic rats. As can be seen in 
Figure 10, similar trends were observed in OGT responses following treatment with OA-
containing dermal patches. Likewise, the blood glucose AUC0-360min was smaller in animals 
treated with OA-containing dermal hydrogel patch matrices compared with respective untreated 
STZ-induced diabetic rats. 
 
The OGT response and AUCglucose 0-360min observed in PI and OA treated animals were not 




In summary, the topical application of pectin insulin and OA-containing dermal hydrogel patches 
on the skin at various doses lowered blood glucose concentrations in a dose independent manner 



























































































Figure 9: Comparison of the effects of PI dermal matrix patches of different insulin 
concentrations on OGT responses (A) and AUCglucose 0-360min (B) in STZ-induced diabetic rats 
with untreated STZ-induced diabetic rats, control non-diabetic (ND) and sc insulin treated 
animals. Values are presented as means, and vertical bars indicate SEM of means (n=6 in each 
group).  = p<0.05 by comparison with untreated animals   
 
 































































 Figure 10: Comparison of the effects of OA-containing dermal matrix patches of different OA 
concentrations on OGT responses (A) and AUCglucose 0-360min (B) in STZ-induced diabetic rats 
with untreated STZ-induced diabetic rats, control non-diabetic (ND) and sc insulin treated 
animals. Values are presented as means, and vertical bars indicate SEM of means (n=6 in each 




3.3. Short-term effects 
The effects of treatment with PI dermal patches on glucose homeostasis were evaluated in 
separate groups of non-diabetic and STZ-induced diabetic rats. Likewise, the effects of treatment 
with OA-containing dermal patches on glucose homeostasis were evaluated. Animals were 
treated thrice daily, 8 h apart over a 5 week experimental period. 
 
3.3.1. Body weight, food and water intake 
 
Body weight, food and water intake were monitored over a period of 5-weeks in STZ-induced 
diabetic animals treated with PI-containing dermal patches to evaluate the effects of transdermal 
treatments on these physical parameters. Tables 2 compare the effects of PI-containing dermal 
patches on daily weight changes, food and water intake of STZ-induced diabetic animals with 
untreated STZ-induced diabetic and control non-diabetic rats over a period of 5-weeks. There 
was a significant increase in water intake and a decrease in the weight of untreated STZ-induced 
diabetic animals in comparison to control non-diabetic animals. Untreated STZ-induced diabetic 
rats exhibited characteristic signs of diabetes such as severe wasting and increased intake of 
water. There was no change in food intake in all groups because all animals were given a 
standard amount of food (30 g /day) hence no polyphagia was observed. The standard amount of 
food was selected based on preliminary studies. Treatment with PI dermal patches containing 
low doses of insulin (3.99 and 9.57µg/kg) significantly reduced the weight loss and water intake 
from week 3 whilst effects of PI dermal patches containing 16.80 µg/kg were observed from 
week 1. Interestingly, effects of PI treatment on body weight, food and water intake were 
comparable to those observed in animals administrated with the standard drug, sc insulin. 
 
On the other hand, Tables 3 compares the effects of OA-containing dermal patches on daily 
weight changes, food and water intake of STZ-induced diabetic animals with untreated STZ-
induced diabetic and control non-diabetic rats over a period of 5-weeks. Similarly, there was no 
change in food intake in all groups since all animals were given a standard amount of food (30 g 
/day) based on preliminary studies hence no polyphagia was observed. Treatment with OA-
containing dermal patches containing low dose of OA (21 mg/kg) significantly reduced the 
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weight loss and water intake from week 3 whilst effects of the median dose (42 mg/kg) and high 
dose (84 mg/kg) were observed from week 1. Similarly, effects of OA treatment on body weight, 
food and water intake were comparable to those observed in animals administrated with the 
standard drug, sc insulin. 
 
In summary, food intake of the non-diabetic control, untreated and all treated STZ-induced 
diabetic animals was not altered throughout the experimental study whilst water intake decreased 
in all treated groups towards the end of the experimental period. All transdermally treated groups 
progressively gained weight exhibiting mean values comparable to those of subcutaneously 
treated groups. Therefore, treatment with PI and OA-containing dermal patches attenuated the 
above mentioned characteristic signs of diabetes to a similar extent by comparison to the 





















Table 2: Comparisons of the effects of PI-containing dermal patches on body weight, food and 
water intake in STZ-induced diabetic rats with untreated diabetic rats, control non-diabetic (ND) 
and sc insulin treated animals. Insulin was administered thrice daily for 5-weeks via 
subcutaneous injection or PI insulin matrices. Data are expressed as mean ± SEM, n=6 in each 
group. 
                                              Time (Weeks) 
Parameter Experimental 
protocol 




ND control 10±1 9±1 10±1 10±1 11±1 
STZ-untreated 12±1 13±1 13±1 13±2 13±1 
STZ-3.99 11±1 12±1 11±2 11±1 11±1 
STZ-9.57 12±1 11±1 11±1 11±1 12±1 
STZ-16.80  11±1 11±1 11±1 11±1 11±1 
STZ-sc ins 
 














































% b.wt  
Change 





































* = p < 0.05 by comparison with control non-diabetic (ND) animals 
 = p < 0.05 by comparison with comparison with untreated STZ-induced diabetic rats 
% b.wt changes = change relative to body weight at the beginning of the study 
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Table 3: Comparisons of the effects of OA matrix patches of different OA concentrations on 
body weight, food and water intake in STZ-induced diabetic rats with untreated diabetic rats, 
control non-diabetic (ND) animals and sc treated animals. OA was administered thrice daily for 
5-weeks via OA-containing dermal matrices. Data are expressed as mean ± SEM, n=6 in each 
group.  
                                              Time (Weeks) 
Parameter Group 1 2 3 4 5 
 ND control  10±1 9±1 10±1 10±1 11±1 
Food intake STZ-untreated 12±1 13±1 13±1 13±2 13±1 
(g/100g) STZ-21 12±1 11±2 12±1 12±2 12±2 
 STZ-42 12±2 13±1 12±1 11±2 11±2 
 STZ-84 12±1 12±1 11±1 12±1 11±2 
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 STZ-sc ins  6±1 3±1 4±2 2±1 3±1
* 
* = p < 0.05 by comparison with control non-diabetic (ND) animals 
 = p<0.05 by comparison with comparison with untreated STZ-induced diabetic rats 




3.3.2. Effects of dermal patches on the skin morphology 
We evaluated the effects of daily treatments by PI-containing dermal patches (16.80 µg/kg) for 
5-weeks on skin morphology of STZ-induced diabetic rats by histological analysis. H and E 
stained skin sections of non-diabetic control and STZ-induced diabetic rats of dermal insulin 
patches observed under light microscope showed no significant histological differences in dermis 
(Figure 11). Compared to control animals, neither inflammation nor necrosis were detected in the 
skin of all PI treated animals as the photomicrographs revealed preserved epidermis after 5 
weeks of daily topical application of the patch (Figure 11).  
 
Similarly, we also evaluated the effects of daily treatments by OA-containing dermal patches (42 
mg/kg) for 5-weeks on skin morphology of STZ-induced diabetic rats by histological analysis. 
Like in PI-treated animals, treatment with OA-containing dermal patches showed neither 
inflammation nor necrosis in the rat skin as the H and E photomicrographs revealed preserved 
epidermis after 5 weeks of daily topical application of the patch (Figure 11). 
 
Interestingly, STZ-induced diabetic rats treated with daily subcutaneous insulin injections did not 
show significant damage in dermal and epidermal layers of the skin when compared to non-
diabetic control and untreated STZ-induced diabetic animals (Figure 11).  
 
In summary, treatment with PI and OA-containing dermal patches did not alter the skin 
morphology of STZ-induced diabetic rats. These results were comparable to those observed in 







Figure 11: Photomicrographs illustrating the effects of dermal insulin (16.80 µg/kg) and OA 
patches (42 mg/kg) on the morphology of the skin in non-diabetic and STZ-induced diabetic rats. 
Picture A represents intact secretory ducts (white arrow), stratum basale (yellow arrow) and 
sebaceous glands (red arrow) of the non-diabetic control animals. Picture B represents intact 
secretory ducts (white arrow), stratum basale (yellow arrow) and sebaceous glands (red arrow) of 
untreated STZ-induced animals. Picture C represents intact secretory ducts (white arrow), 
stratum basale (yellow arrow) and sebaceous glands (red arrow) of the PI treated animals. Picture 
D represents intact secretory ducts (white arrow), stratum basale (yellow arrow) and sebaceous 
glands (red arrow) of OA treated animals. Picture E represents intact secretory ducts (white 
arrow), stratum basale (yellow arrow) and sebaceous glands (red arrow) of the subcutaneously 






3.3.3. Effects of dermal patches on IRS 
To establish whether insulin was transported across skin of STZ-induced diabetic rats following 
topical application of PI-containing dermal matrix patches (16.80 µg/kg), we monitored the 
density of phosphorylated insulin receptor substrates (IRS) in skin tissues by 
immunohistochemical staining. Skin fragments obtained from STZ-induced diabetic rats for 
immunohistochemistry of IR contained cellular elements from the epidermis and dermis, 
including hair follicles and glandular structures (Figure 12). The method control skin section 
showed faint negative immune-reactivity (Figure 12A). Untreated non-diabetic rat skin sections 
exhibited intense widespread localization of IRS (Figure 12B) compared to faint staining of 
untreated STZ-induced diabetic control rats (Figure 12C). Immunohistochemical staining for 
phosphorylated IRS in the skin of animals following application of insulin-containing dermal 
patches and sc insulin for 5 weeks clearly demonstrated widespread localization of IRS in cell 
bodies of the dermis, collagen and subcutaneous layer (Figure 12D and Figure 12E), 
respectively. The higher magnification of transdermal insulin treated rat skin section confirmed 
widespread localization of IRS (Figure 12F).  
 
Similar experiments were conducted for OA-containing dermal patches (42 mg/kg) to establish 
whether OA was also transported across skin of STZ-induced diabetic rats. Likewise, topical 
application of OA-containing dermal patches also demonstrated widespread localization of IRS 
in cell bodies of the dermis, collagen and subcutaneous layer (Figure 12G) which were 
significantly different from the faint staining of untreated STZ-induced diabetic rats but 
comparable to the intense staining of non-diabetic control animals. 
 
In summary the widespread localization of IRS in cell bodies of the dermis, collagen and 
subcutaneous layer evoked by PI and OA-containing dermal patches were comparable to those 







Figure 12: Immunohistochemical micrographs illustrating the effects of PI (16.80 µg/kg) and 
OA (42 mg/kg) dermal patches on the expression of insulin receptor (IR) in skin sections of 
STZ-induced diabetic rats. The presence of IRS is depicted as brown staining and a method 
control (A) reveals no immune-reactivity and intense haematoxylin staining (blue) across 
epidermis and dermis. Non-diabetic control rat skin section (B) revealed widespread localization 
of IRS across the epidermis and dermis. Untreated STZ-induced diabetic rat skin section (C) 
exhibited very low immuno-reactivity predominantly in the dermis. Intense immuno-reactivity 
was observed in the epidermis, dermis and subcutaneous layer of transdermal insulin treated rat 
skin section (D). Subcutaneous insulin treated rat skin section (E) and transdermal OA treated rat 
skin section (G) also exhibited widespread localization of IRS in the epidermis and dermal 
structures. (Mag. 4× 500µm). All the dermal structures including, collagen, hair follicles, 
sebaceous glands and blood vessels were positive for IRS with more intensity in the insulin 




3.3.4. Effects of dermal patches on the pancreas morphology   
 
The effects of STZ administration and daily treatment with PI-containing dermal patches (16.80 
µg/kg) in separate groups of non-diabetic and STZ-induced diabetic rats were evaluated on 
pancreas morphology after the 5 week experimental period. 
 
H and E stained pancreas sections of untreated STZ-induced diabetic rats showed altered 
architecture and decreased number of islets, as indicated by the arrows, when compared to the 
non-diabetic control animals. STZ-induced diabetic rats topically applied with PI-containing 
dermal patches observed under light microscope showed significant histological differences in 
normal architecture and decreased number of islet in comparison to non-diabetic control animals 
(Figure 13). Interestingly, the sc treated group also showed significant histological differences in 
normal architecture and decreased number of islet in comparison to non-diabetic control animals. 
 
Similar experiments were conducted following STZ administration and daily treatment with OA-
containing dermal patches (42 mg/kg). Significant histological differences in normal architecture 
and decreased number of islet were also observed in OA treated animals in comparison to non-
diabetic control animals (Figure 13). 
 
In summary, daily treatment by topical application of insulin-containing and OA-containing 
dermal as well as sc treatment did not have an effect on the necrotic changes caused by STZ on 




Figure 13: Photomicrographs illustrating the effects of STZ on the morphology of the pancreas 
in non-diabetic and STZ-induced diabetic rats. Picture A illustrates normal pancreatic islets of 
non-diabetic control animals. Picture B, C, D and E illustrates severe necrotic changes and 
altered architecture and number of islets of untreated, PI-treated (16.80 µg/kg), OA-treated (42 












3.4. Biochemical analyses 
To assess the chronic effects of the novel transdermal formulations on selected metabolic 
parameters, a 5 week study was conducted where PI-containing dermal patches were 
administered thrice daily, 8 hours apart. The same dosing regime was applied for sc insulin 
administration. Similar experiments were also conducted for OA-containing dermal patches. 
Consistent with our use of a diabetic animal model, untreated STZ-induced diabetic rats 
maintained high blood glucose values throughout the experiment and exhibited extensive 
depletion of glycogen in liver and muscle tissues by the end of the 5-week study period (Figure 
14 and 15; Table 3 and 4). The reduction in glycogen production was associated with decreased 
expressions of the insulin-stimulated GS and GLUT-4 in hepatic and skeletal muscle tissues, 
respectively (Figure 18). However, treatment with PI dermal patches (16.80 µg/kg) like insulin 
(175 µg/kg, sc) restored the expressions of GLUT-4 and GS to levels comparable to values of 
non-diabetic control animals (Figure 18). Treatment with PI-containing dermal patches also 
caused a significant increase in antioxidant activity with a corresponding decrease in MDA 
levels in skin tissue samples (Table 7). In addition, our transdermal formulations decreased 
plasma creatinine concentrations and increased GFR without altering with the plasma urea 
concentrations (Table 5 and 6).  
 
Likewise, treatment with OA-containing dermal patches also caused a significant increase in 
antioxidant activity with a corresponding decrease in MDA levels in skin tissue samples (Table 
7). Furthermore, OA-containing dermal patches decreased plasma creatinine concentrations and 
increased GFR without altering with the plasma urea concentrations (Table 5 and 6).  
 
In summary, transdermal treatment lowered blood glucose concentrations with concomitant 







3.4.1. Effects on blood glucose concentrations 
Blood glucose concentrations were monitored over a 5-week experimental period in separate 
groups of non-diabetic and STZ-induced diabetic rats treated with various doses of PI- 
containing dermal patches thrice daily, 8 hours apart (Figure 14). Similar experiments were 
carried out for OA-containing dermal patches (Figure 15).  
The blood glucose concentrations of non-diabetic control animals remained within euglycaemic 
levels throughout the experimental period. Conversely, the blood glucose concentrations of 
untreated STZ-induced diabetic animals remained significantly high in comparison to the non-
diabetic control animals throughout the experimental period (Figure 14 and 15). 
  
There was no significant change in blood glucose concentrations in the first week of treatment in 
groups treated with PI dermal patches containing 3.99 and 9.57 µg/kg insulin. However, a 
significant reduction in blood glucose concentrations was observed in the first week of treatment 
in groups treated with the highest dose (16.80 µg/kg) and sc insulin (175 µg/kg) in comparison to 
untreated STZ-induced diabetic animals. The decrease in blood glucose concentration reached 
statistical significance in all STZ-treated groups as from the second week to the end of the 
experimental period in comparison to untreated STZ-induced diabetic animals.  
 
Figure 15 shows that there was no significant reduction in blood glucose concentrations in the 
first week of treatment in groups treated with the low (21 mg/kg) and high dose (84 mg/kg) of 
OA. However, a significant reduction in blood glucose concentrations was observed in the first 
week of treatment in groups treated with the median dose (42 mg/kg) and insulin (175µg/kg) in 
comparison to untreated STZ-induced diabetic animals. The decrease in blood glucose 
concentration reached statistical significance in all STZ-treated groups as from the second week 
to the end of the experimental period in comparison to untreated STZ-induced diabetic animals. 
Administration of the standard drug (insulin, sc) demonstrated blood glucose-lowering effects in 
STZ-induced diabetic rats to euglycaemic level as expected. Interestingly, the reduced blood 
glucose concentrations in all transdermally treated groups were not significantly different from 




In summary, topical application of PI and OA-containing dermal patches reduces blood glucose 
concentrations in STZ-induced diabetic rats. 
 
 

















































Figure 14: Comparison of the effects of PI dermal matrix patches on blood glucose 
concentration in STZ-induced diabetic rats with untreated diabetic rats, control non-diabetic 
(ND) and sc insulin treated animals. Animals treated with drug-free pectin and subcutaneous 
insulin (175µg/kg) acted as negative and positive controls, respectively. Values are presented as 
means, and vertical bars indicate SEM of means (n=6 in each group).  = p<0.05 by comparison 
with control animals; ♦ = p < 0.05 by comparison with non-diabetic control animals; ● = p<0.05 






















































Figure 15: Comparison of the effects of transdermally delivered OA on blood glucose 
concentration in STZ-induced diabetic rats with untreated diabetic rats, control non-diabetic 
(ND) and sc insulin treated animals. Animals treated with drug-free pectin and insulin 
(175µg/kg) acted as negative and positive controls, respectively. Values are presented as means, 
and vertical bars indicate SEM of means (n=6 in each group).  = p<0.05 by comparison with 
respective control animals; ♦ = p < 0.05 by comparison with non-diabetic control animals; ● = 








3.4.2. Effects on plasma insulin concentrations 
To elucidate the possible mechanisms responsible for the hypoglycaemic effects exerted by 
topical application of PI-containing dermal patches, blood was collected from separate groups of 
non-diabetic and STZ-induced diabetic rats. The possible mechanisms responsible for the 
hypoglycaemic effects exerted by topical application of OA-containing dermal patches were also 
investigated. Plasma insulin concentrations were measured from samples collected after 6 hours 
(acute) and after 5 weeks (chronic) of experimental period. Animals from which acute plasma 
samples were collected were starved for 18 h prior to the experiment whereas animals from 
which chronic plasma samples were collected were given a standard amount of food based on 
preliminary studies.  
 
The plasma insulin concentration remained very low in the untreated STZ-induced diabetic 
group in comparison to the non-diabetic control group (Figure 16 and 17). Interestingly, the 
plasma insulin concentrations were elevated in the PI treated groups after the 6 hour 
experimental period. However, the levels induced by low doses (2.47 and 3.99 µg/kg) were 
significantly smaller than those induced by high doses (9.57 and 16.80 µg/kg). In addition, the 
increased insulin concentrations in all PI treated groups was not significantly different from 
those observed in the group treated with the standard drug (insulin, sc). These data indicate that 
insulin was transported from insulin-containing dermal patches into the blood in a dose-
dependent manner. Similar trends were observed in the plasma insulin concentrations measured 
after 5 weeks.  
 
On the other hand, there was no change in plasma insulin concentrations of STZ-induced 
diabetic rats following acute and short-term daily treatment with OA-containing dermal patches. 
The plasma insulin concentrations remained significantly low in all OA-treated groups at the end 
of the 6 h and 5-week experimental period in comparison to the non-diabetic control animals 
(Figure 17). Interestingly, the reduced plasma insulin concentrations in all OA treated groups 




In summary, PI treatment increased plasma insulin concentrations whereas treatment with OA-



































































Figure 16: Comparison of the effects of PI matrix patches of different insulin concentrations on 
plasma insulin concentrations in STZ-induced diabetic rats with untreated diabetic rats, control 
non-diabetic (ND) and sc insulin treated animals. Values are presented as means, and vertical 
bars indicate SEM of means (n=6 in each group). ♦ = p<0.05 by comparison with non-diabetic 
control;  = p<0.05 by comparison with untreated STZ-induced diabetic rats; ● = p<0.05 by 



















































Figure 17: Comparison of the effects of OA matrix patches of different OA concentrations on 
plasma insulin concentrations in STZ-induced diabetic rats with untreated diabetic rats, control 
non-diabetic (ND) and sc insulin treated animals. Values are presented as means, and vertical 
bars indicate SEM of means (n=6 in each group). ♦ = p<0.05 by comparison with non-diabetic 




3.4.3. Effects on glycogen concentrations 
Hepatic and muscle glycogen concentrations were measured in separate groups of non-diabetic 
and STZ-induced diabetic rats after 5 weeks of treatment with PI-containing dermal patches to 
elucidate the mechanisms responsible for the hypoglycaemic effects induced by treatment. 
Similarly, hepatic and muscle glycogen concentrations were also measured in separate groups of 
non-diabetic and STZ-induced diabetic rats after 5 weeks of treatment with OA-containing 
dermal patches.  
 
Untreated STZ-induced diabetic rats exhibited extensive hyperglycaemia and depletion of liver 
and muscle glycogen concentrations by the end of the 5-week experimental period in comparison 
to non-diabetic control animals (Table 4). 
 
All PI treated groups significantly increased glycogen concentrations of both tissues in 
comparison to respective control animals. Interestingly, the PI treated groups showed no dose-
dependent effect, however, the effects of PI treated groups were comparable to those of the 
subcutaneously treated groups (Table 4). 
 
Likewise, all OA treated groups exhibited significantly reduced glucose concentrations with 
concomitant increase in hepatic and muscle glycogen concentrations in comparison to untreated 
STZ-induced diabetic rats (Figure 15 and Table 4). All OA treated groups restored the depleted 
hepatic and muscle glycogen concentrations to levels near normalcy. However, the increase in 
hepatic glycogen concentrations following treatment with OA-containing dermal patches was 
found to be significantly different to the non-diabetic control group (Table 4).  
 
In summary, these results show that topical application of pectin insulin- or OA-containing 
dermal patches reduce blood glucose concentrations and increases liver and muscle glycogen 






Table 4: Comparisons of the effects of PI and OA –containing dermal patches on hepatic and 
muscle glycogen concentrations in STZ-induced diabetic rats with untreated diabetic rats, control 
non-diabetic (ND) animals and sc insulin treated animals. Drugs were administered thrice daily 
for 5-weeks via PI and OA dermal matrices as well as subcutaneous injections. Values are 
presented as mean ± SEM (n=6 in each group).  
 
 Glucose mmol/L Glycogen µg/100g/tissue 
  Hepatic Skeletal muscle 
Non-diabetic control 4.51 ± 0.01 28.42 ± 0.41 2.62 ± 0.32 
STZ-untreated 29.83 ± 2.01
♦
 12.36 ± 0.72
♦
 1.02 ± 0.21
♦
 
STZ-induced : PI 3.99 7.13 ± 0.28
*
 20.08 ± 0.56
*
 2.02 ± 0.09
*
 
STZ-induced : PI 9.57 6.65 ± 0.18
*
 21.26 ± 0.64
*
 2.34 ± 0.20
*
 
STZ-induced : PI 16.80 6.63 ± 0.07
*
 22.02 ± 1.33
*
 2.52 ± 0.38
*
 
STZ-induced : OA 21 7.98 ± 0.18
*
 18.64 ± 0.76
*♦
 2.00 ± 0.11
*
 
STZ-induced : OA 42 7.54 ± 0.15
*
 18.90 ± 0.97
*♦
 2.20 ± 0.13
*
 
STZ-induced : OA 84 8.19 ± 0.36
*
 17.74 ± 0.53
*♦
 1.83 ± 0.16
*
 
STZ-induced sc ins 5.95 ± 0.11
*
 21.28 ± 0.94
*




 = p<0.05 by comparison with untreated STZ-induced diabetic animals 
 














3.4.4. Effects on urea and creatinine concentrations   
Plasma creatinine and urea concentrations were measured in separate groups of STZ-induced 
diabetic rats after 5 weeks of treatment with PI-containing dermal patches to establish whether 
treatment alleviates the renal complications associated with hyperglycaemia. Similar experiments 
were also carried out in separate groups of STZ-induced diabetic rats after 5 weeks of treatment 
with OA-containing dermal patches. 
 
Plasma creatinine concentrations were significantly elevated in untreated STZ-induced diabetic 
rats by comparison with untreated non-diabetic rats at the end of the 5 week experimental period 
whilst plasma urea concentration was slightly increased to levels that did not achieve statistical 
significance (Table 5 and 6). The dermal PI matrix patch with highest insulin (16.80 µg/kg) 
significantly reduced plasma creatinine concentration in STZ-induced diabetic rats with a 
concomitant increase in GFR (Table 5).  
 
Similarly, the dermal OA-containing patches with median dose (42 mg/kg) and highest dose (84 
mg/kg) significantly reduced plasma creatinine concentrations with a concomitant increase in 
GFR (Table 6). However, plasma urea concentration was not altered by any of the treatments.  
 
In summary, treatment of STZ-induced diabetic rats with PI or OA-containing dermal patches 
decreased plasma creatinine concentrations and increased GFR without altering with the plasma 












Table 5: Comparisons of the effects of PI–containing dermal patches on terminal plasma 
creatinine and urea in STZ-induced diabetic rats with untreated diabetic rats, control non-diabetic 
(ND) animals and sc insulin treated animals. Insulin was administered thrice daily for 5-weeks 
via subcutaneous injection or PI insulin matrices. Data are expressed as mean ± SEM, n=6 in 
each group. 
 













Urea (mmol/L) 7.31 ± 0.92 9.82 ± 1.43 8.82 ± 0.98 9.41 ± 0.94 7.12 ± 0.72 8.52 ± 0.41 
Creatinine  
(µmol/L) 
25.23 ± 0.01 37.50 ± 0.04* 36.21 ± 0.03* 
 
35.80 ± 0.75* 34.31 ± 2.70 33.21 ± 0.03 
GFR 
ml/min/100 g  
0.85 ± 0.11 0.41 ± 0.12* 0.69 ± 0.12 0.71 ± 0.22 0.81 ± 0.31 0.74 ± 0.20 
 
* = p< 0.05 by comparison with non-diabetic control animals 
 














Table 6: Comparisons of the effects of OA–containing dermal patches on terminal plasma 
creatinine and urea in STZ-induced diabetic rats with untreated diabetic rats, control non-diabetic 
(ND) animals and sc insulin treated animals. OA or insulin was administered thrice daily for 5-
weeks via pectin OA dermal matrices or subcutaneous injections, respectively. Data are 
expressed as mean ± SEM, n=6 in each group. 















Urea (mmol/L) 7.31 ± 0.92 9.82 ± 1.43 7.61 ± 0.84 8.24 ± 0.64 9.04 ± 0.82 8.41 ± 0.81 
Creatinine  
(µmol/L) 
25.23 ± 1.12 35.50 ± 1.24* 34.14 ± 0.94* 33.62 ± 1.14* 32.24 ± 0.45* 33.11 ± 0.73* 
GFR 
ml/min/100 g  
0.85 ± 0.11 0.41 ± 0.12* 0.66 ± 0.22 0.61 ± 0.22 0.70± 0.21 0.74 ± 0.20 
* = p< 0.05 by comparison with non-diabetic control animals 
 














3.4.5. Effects on oxidative stress (MDA, SOD and GPx)  
The highest dose of PI dermal patches (16.80 µg/kg) was selected to establish the effects of PI-
containing dermal patches on MDA, SOD and GPx in the skin tissue samples. The 
concentrations of MDA and antioxidant enzymes (SOD and GPx) in non-diabetic control 
animals represent baseline/normal activity levels found in the skin tissues (Table 7). Significant 
increase of MDA and decreases of SOD and GPx were found in the skin tissue of untreated STZ-
induced diabetic animals as compared to non-diabetic control animals. PI-containing dermal 
patches significantly reduced the concentrations of MDA and increased the activities of SOD and 
GPx in the skin tissues compared to untreated STZ-induced diabetic animals. These antioxidant 
effects of PI-containing dermal patches were similar to those of sc insulin. 
 
Similarly, the median dose of OA-containing dermal patches (42 mg/kg) was selected to 
establish the effects of OA-containing dermal patches on MDA, SOD and GPx in the skin tissue 
samples. Like the PI-containing dermal patch, the OA-containing dermal patches significantly 
reduced the concentrations of MDA and increased the activities of SOD and GPx in the skin 
tissues compared to untreated STZ-induced diabetic animals. These antioxidant effects of OA-
containing dermal patches were comparable to those of sc insulin. 
 
 
In summary, treatment with PI and OA-containing dermal patches caused a significant increase 












Table 7: Comparisons of the effects of PI and OA –containing dermal patches on MDA 
concentration, activities of SOD and GPx in skin tissues of STZ-diabetic rats with untreated 
diabetic rats, control non-diabetic (ND) animals and sc insulin treated animals. Drugs were 
administered thrice daily for 5-weeks via PI and OA dermal matrices as well as subcutaneous 
injections. Values are presented as means ± SEM (n=6 in each group). 
Parameter Treatment 






MDA (nmol /g 
protein) 
1.25 ± 0.01 6.02 ± 0.03
*










2.56 ± 0.07 1.95 ± 0.03 2.96 ± 0.04 
GPx activity (nmol 
min/ml/g protein) 
0.16 ±  
0.09 
 
0.02 ±  0.01
*
 0.15 ± 0.01 0.12 ± 0.01 0.15 ± 0.02 
* = p< 0.05 by comparison with non-diabetic (ND) control animals 













3.4.6. Western blot analyses 
Western blots were performed to evaluate the effects of PI dermal patches on insulin dependent 
glucose transporters and glycogenic enzymes in STZ-induced diabetic rats. To determine 
whether the conversion of glucose to glycogen was influenced by insulinometric glucose 
transporters and glycogenic enzymes, we determined the expression of GLUT-4 and GS in the 
gastrocnemius muscle and liver tissues, respectively (Figure 18). The GLUT-4 and GS 
expression were significantly reduced in both tissues of untreated STZ-induced diabetic rats in 
comparison to the non-diabetic control groups. The PI treated group restored the expression of 
GLUT-4 and GS to levels that were comparable to the non-diabetic control animals. Treatment 
with sc insulin increased the expression of GLUT-4 and GS. This increase was comparable to 
that of the PI treated group. 
 
In summary, PI dermal patches restore the depleted expression of GLUT-4 and GS in the 











Figure 18: Comparison of the effects of topically applied PI hydrogel matrix patch on the the 
insulin-stimulated glycogen synthase (GS) and facilitative glucose transporter (GLUT-4) in 
hepatic and skeletal muscle tissues of STZ-induced diabetic rats, respectively with untreated 
non-diabetic animals and sc insulin treated animals  as determined by Western blotting. Values 
are expressed as mean ± S.E.M. Values were obtained from Western blots for six preparations. 














The current study investigated whether transdermal application of PI dermal patches sustains 
controlled insulin release into the bloodstream of STZ-induced diabetic rats and alleviate 
selected diabetic symptoms. The results show that transdermal application of PI matrix patches 
of different insulin concentrations sustain controlled release of insulin into the bloodstream of 
STZ-induced diabetic rats with concomitant increases in liver and muscle glycogen levels. 
Similarly PI treatment lowered the blood glucose of both non-diabetic and diabetic rats with 
concomitant restoration of glycogen concentrations, GLUT-4 and GS expressions to near 
normalcy in the latter animals. 
 
This study further substantiates the current knowledge of glucose homeostasis where exogenous 
insulin is known to exert blood glucose lowering effects in experimental diabetic animals with 
non-functional pancreatic β-cells (Liu et al., 2007; Tang et al., 2008). We utilized STZ-induced 
diabetic rats, the widely used animal model of human diabetes. The induction of experimental 
diabetes in male Sprague-Dawley rats (250-300g) was achieved by using STZ which selectively 
destroys pancreatic β-cells. STZ is a commonly used diabetogenic agent in both type 1 and type 
2 diabetes. However, the effects of STZ are dependent on the dose and the route of 
administration (Szkudelski, 2001). Observations revealed that a single intraperitoneal injection of 
STZ (60 mg/kg) selectively destroyed or impaired secretion of insulin from β cells of the pancreas 
and the systemic changes which occur after are related to the induced diabetic state (Grant et al., 
1973; Krusteva et al., 1990; Li et al., 2005; Lenzen, 2008). However, the traces of insulin observed 
in STZ-induced diabetic rats were perhaps due to the detection of insulin-like growth factors in the 
blood. The effects of STZ were validated by pancreas histological analyses after 5 weeks which 
showed significant histological differences in normal architecture and number of islet of STZ-
induced diabetic rats in comparison to non-diabetic control animals. However, treatment with PI-
containing dermal patches did not have an effect on the necrotic changes caused by STZ on the 
pancreatic cells after 5 weeks. These histological changes could be attributed to the deoxyglucose 
moiety of STZ cells which facilitates the entry of this diabetogenic agent into β-cells as well as 
the nitrosourea property which makes STZ a selectively toxic agent (Coskun et al., 2005; 
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Srinivasan and Ramarao, 2007). The entry of STZ through GLUT-2 transporters into the 
pancreatic β cells causes toxicity and DNA damage which ultimately leads to β cell death 
(Weiss, 1982; Pinent et al., 2004; Li et al., 2005). Reports suggest that the β cell destruction is 
due to the activation of poly ADP-ribosylation following DNA damage. This activation leads to 
a reduction in cellular NAD
+
 and ATP with concomitant inhibition of insulin synthesis and 
secretion (Szkudelski, 2001; Gao et al., 2009).  
 
The key to strict glycaemic control with exogenous insulin lies in delivery methods that maintain 
physiological insulin concentrations. Trials on oral administration of insulin have been 
conducted in our laboratory using pectin as a vehicle. Previous studies have reported that insulin-
loaded amidated pectin hydrogel bead formulation sustains controlled insulin release in diabetic 
rats and lower blood glucose concentration in STZ-induced diabetic rats (Musabayane et al., 
2000). Pectin has been used as a carrier of a wide variety of biologically active agents, for 
sustained release applications and targeting drugs to the colon for either local treatment or 
systemic action (Krusteva et al., 1990; Musabayane et al., 2000). The digestion of pectin in 
insulin-loaded amidated pectin hydrogel beads by the intestinal flora that inhabit the colon 
resulted in the release of insulin in dosage form. Building on these previous observations, novel 
insulin- and OA-containing dermal patch cocktails capable of delivering drugs into the 
bloodstream were developed in the current study and investigated for their loading efficiency, 
stability and ability to deliver sustained amounts of the drugs into the blood circulation.  
 
The pectin hydrogel dermal matrix cocktail comprised of (a) low methoxy (LM) pectin gelled 
with calcium ions (b) insulin or OA (c) a transdermal transfer enhancing agent and (d) an 
antioxidant. The findings of this study indicate that we were able to develop a novel insulin 
transdermal formulation as evidenced by percentage insulin loading efficiencies. The PI dermal 
patch achieved percentage insulin loading efficiencies ranging from 76 to 94% in the various 
patches. The high loading efficiency of insulin in the pectin matrix patches was probably due to 
amidated low methoxy pectin and calcium ions for proper gel formation. LM pectin has the 
lowest level of esterification which increases the sensitivity of pectin to cations in the process of 
gelation. The mechanism of LM-pectin gelation relies mainly on the well-known ‘egg-box’ 
model (Grant et al., 1973) whereby specific parallel or adjacent chains are linked 
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intermolecularly through electrostatic and ionic bonding of carboxyl groups.  The doses of 
insulin (3.99, 9.57, 16.80 µg/ kg) derived from pectin dermal patches with an acceptable range of 
percentage insulin loading efficiencies compare with those previously used in human studies 
(6.25–17.86 μg/kg) (Karande et al., 2002; Sen et al., 2002). The physiochemical analyses of our 
transdermal formulation indicated that the PI dermal matrix patch is stable for two months as 
evidenced by constant insulin concentrations. The stability of insulin in formulations is an 
important issue since aggregation of insulin is known to lead to severely reduced biological 
activity (Brange, 1987). Therefore, the recovery percentages of insulin with the original insulin 
activity after 2 months storage proved good stability of PI dermal matrix patch.   
 
The structural elucidation of S. aromaticum-derived OA permitted the use of isolated OA to 
carry out experiments since the absolute stereostructure of S. aromaticum-derived OA elucidated 




C-NMR was comparable to the previously reported data 
(Mahato and Kundu, 1994; Mapanga et al., 2009; Uddin et al., 2011). However, dissolution 
studies were not conducted in OA-containing dermal patches as we were yet to develop a 
standardized method of quantifying triterpenes. 
 
Although the oral method of drug delivery proved to be successful, OA does not dissolve easily 
in water hence the need to assess the therapeutic efficacy of OA via the transdermal route. The 
results show that topical application of pectin OA-containing dermal patches to STZ-induced 
diabetic rats does not affect plasma insulin concentrations but reduces blood glucose levels and 
increases liver and muscle glycogen levels in hepatic and skeletal muscle tissues, respectively. 
The pharmacokinetics of OA were not measured in this study as we were yet to develop a 
standardized method of quantifying triterpenes in the plasma of rats despite the paucity of data 
documenting measurement of OA in human plasma. The magnitude in which our novel 
transdermal formulations exerted blood glucose-lowering effects with concomitant alleviation of 
some diabetic symptoms was comparable to those of the positive control (sc insulin). These 
observations are of considerable importance because application of PI and OA-containing dermal 
patches would free diabetic patients from daily bolus injections needed to maintain a constant 
insulin concentration. The PI and OA-containing dermal hydrogel matrix patches would also 




Takeuchi et al., has demonstrated that the rat skin may be used as a substitute for the human skin 
in in vitro skin permeation studies (Takeuchi et al., 2011).  To avoid pruritus and the risks of 
them scratching the patch off each other, animals were shaved a day prior to experimental 
procedures and placed in individual cages. The patch concoction did not show any detrimental 
effects on the morphology of underlying tissues of the skin as evidenced by histological 
observations. Neither inflammation nor necrosis was detected in the skin of the rats after five 
weeks of daily treatment with PI-containing dermal patches. This could be attributed to the 
protective effect of the antioxidants, vitamin E and eucalyptus oil in the patch. These protective 
effects evoked by the concoction in PI-containing dermal patches were corroborated by a 
significant increase in antioxidant activity with a corresponding decrease in MDA levels in skin 
tissue samples. Similar effects were observed in OA-containing dermal patches. 
 
Successful transdermal delivery of insulin was corroborated with the observation of extensive 
expression of IRS in the skin of STZ-induced rats following application of PI-containing dermal 
patches. This suggested that the pectin hydrogel insulin patches have the potential to deliver 
insulin across the skin and into the blood stream. The insulin receptor, a transmembrane 
glycoprotein present in virtually all vertebrate tissues undergoes tyrosyl autophosphorylation in 
response to insulin binding to the extracellular α-subunit (Kasuga et al., 1982; White and Kahn, 
1994; Wertheimer et al., 2000; Di Carli et al., 2003). The autophosphorylation of tyrosine kinase 
causes the activation of PI-3-K which results in the translocation of the vesicle containing the 
GLUT-4 transporter to the membrane so that glucose can enter the cell (Shepherd et al., 1998; 
Rios, 2008; Daisy et al., 2010). Glucose entry into muscle and adipose tissue depends on the 
expression of GLUT-4 transporters whereas the entry of glucose in the liver depends on the 
expression of GLUT-2 transporters (Rios, 2008). Interestingly, insulin released from PI-
containing dermal patches enhanced the tyrosine kinase activity of the receptor towards the 
expression of IRS in the skin of STZ-induced rats (Sun et al., 1991; Pelicci et al., 1992; Pronk et 
al., 1993; Araki et al., 1994) and in insulin target tissues such as skeletal muscle and the liver 
(Sun et al., 1991). Similar effects were observed in the skin of STZ-induced rats following 
application of OA-containing dermal patches suggesting that OA uses the same mode of action 
as insulin. Interestingly, the effects exerted by the dermal patches were comparable to those of 
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the standard drug.  We suggest that insulin and OA were released from the patch as a result of 
solubilization of pectin gels by hydroxyl ions (Munjeri et al., 1997), and also because of 
increases in electrostatic repulsions between pectin molecules resulting from hypo-osmotic 
conditions (Cunha et al., 1997). 
 
Diabetes has been associated with polyphagia, polyuria and polydipsia which are mediated by 
the inability of cells to utilise glucose (Arul et al., 2004; Association, 2006). Accordingly, 
untreated diabetic rats exhibited characteristic signs of diabetes such as severe wasting and 
increased intake of water. This could be attributed to polyuria which ultimately leads to 
polydipsia (Rebsomen et al., 2005). Treatment with PI-containing dermal patches reduced water 
intake at the end of the 5-week experimental period perhaps due to increased sodium excretion 
and improved glycaemic control. This speculation can be supported by a decrease in plasma 
creatinine concentration and an increase in GFR without altering the plasma urea concentrations 
of STZ-induced diabetic rats treated with PI-containing dermal patches. These symptoms were 
attenuated in animals treated with PI-containing dermal patches indicating that our novel 
transdermal formulation might have beneficial effects on the management of diabetes. 
Polyphagia was not observed in animals treated with PI-containing dermal patches since all 
animals were given a standard amount of food based on preliminary studies. The non-diabetic 
control rats demonstrated an increase in weight throughout the study whereas untreated STZ-
induced diabetic rats showed a progressive decrease in weight. This significant difference 
between the groups could be due to the anabolic effects of insulin (Chandramohan et al., 2008). 
Interestingly, the novel transdermal formulation stabilised body weight of STZ-induced diabetic 
rats which may be attributed to the incorporation of glucose into cells resulting in an increase in 
glucose utilisation (Okine et al., 2005). Likewise, OA-containing dermal patches averted the 
above mentioned characteristic signs of diabetes. 
 
 
Indeed, systemic changes occurred as a result of STZ administration as well as the application of 
our novel transdermal formulations. Untreated STZ-diabetic rats exhibited significantly lower 
plasma insulin concentration and increased blood glucose concentrations compared to non-
diabetic rats perhaps due to destruction of pancreatic β-cells (Szkudelski, 2001; Pinent et al., 
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2004; Li et al., 2005; Lenzen, 2008). PI hydrogel matrix patches evoked changes in blood 
glucose and plasma insulin concentrations which were comparable to positive control 
experiments using sc insulin. Literature evidence has shown that the subcutaneous injection of 
insulin is the conventional method used in the delivery of this drug into the systemic circulation 
(Mason et al., 2002). This route of drug administration is associated with multiple injections 
which may lead to local skin irritation and thus may contribute to patient non-compliance 
(Mason et al., 2002; Sonaje et al., 2010). Furthermore, insulin administration via the 
subcutaneous route can result in hyperinsulinaemia due to the release of insulin in large amounts. 
Indeed, the sc treated group significantly increased plasma insulin concentrations after 6 hours of 
treatment in comparison to untreated STZ-induced diabetic rats. However, the plasma insulin 
concentrations of the sc treated group remained low within levels that were comparable to those 
of the STZ-induced diabetic group after 5 weeks of treatment. These findings suggest that drugs 
administration via the subcutaneous or oral routes are susceptible to first pass degradation by the 
liver as well as gastrointestinal metabolism (Prausnitz and Langer, 2008). As a result of this 
degradation high drug concentrations (175 µg/kg) are required for therapeutic effects (Prausnitz 
and Langer, 2008). Conversely, there is no first pass metabolism by the liver in transdermal 
delivery system hence low drug concentrations are required (3.99, 9.57 and 16.80 µg/kg). These 
observations indicate that the pharmacokinetics and the route of insulin administration play a 
vital role in the management of diabetes treatment. The success in PI hydrogel matrix patches 
lies on the ability to provide a sustained controlled release of insulin into the bloodstream as 
evidenced by an increase in plasma insulin concentrations to levels that were comparable to 
those of the non-diabetic control after the 6 h experimental period. Therefore, these findings 
suggest that insulin was indeed transported from the matrix patch through the skin into the 
bloodstream to exert hypoglycaemic effects.  
 
Similar blood glucose lowering effects were observed in STZ-induced diabetic rats treated with 
OA-containing dermal patches. The doses of OA in pectin dermal patches (21, 42, 84 mg/ kg) 
were selected on the basis of previous studies (Mapanga et al., 2009; Musabayane et al., 2010; 
Ngubane et al., 2011; Madlala et al., 2012). OA-containing dermal patches reduced blood 
glucose concentrations in STZ-induced diabetic rats though there was no change in plasma 
insulin concentrations. Herbal extracts containing triterpenoids, ursolic acid and corosolic acid 
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have been reported to enhance the blood glucose lowering effects in experimental animals 
(Hayashi et al., 2002; Miura et al., 2004; Jung et al., 2007). Previous studies have shown that 
oral administration of OA decreased plasma glucose concentrations in both non-diabetic and 
STZ-induced diabetic rats following treatment for 5 weeks. However, the reduction in blood 
glucose concentrations of STZ-induced diabetic rats did not achieve euglycaemia (Mapanga et 
al., 2009). Literature evidence has also shown that the peak hypoglycaemic effect of triterpene 
containing herbal extracts occurs 2-4 hours after administration with blood glucose 
concentrations returning to baseline levels in 6-10 hours (Kakuda et al., 1996). This is 
contradictory to the results of the current study because of experimental design and most 
importantly the route of administration. Reports have shown that transdermal formulations using 
pectin as a vehicle releases drugs such as chloroquine and insulin in a sustained and controlled 
manner (Musabayane et al., 2003; Tufts and Musabayane, 2010). Therefore, the pronounced 
blood glucose-lowering effects evoked by OA-containing dermal patches at the end of the 5 
week experimental period may be attributed to the ability of pectin to entrap the drug in the 
matrix and provide a slow sustained release of the drug into the bloodstream. In addition, the 
cross links in the matrix by ionic bonds between the carboxyls of pectin are of vital importance 
in the entrapping of drugs for transdermal delivery (Sriamornsak, 2003). The significant decrease 
in blood glucose concentrations induced by OA-containing dermal patches did not alter plasma 
insulin concentrations. Furthermore, OA could not be expected to have a significant effect on 
insulin concentrations in STZ-induced diabetic rats because of STZ administration which would 
have selectively destroyed the pancreatic β-cells (Pinent et al., 2004). Therefore, the involvement 
of insulin as a hypoglycaemic mechanism is excluded in this case. Reports have shown that OA 
alters glucose metabolism in the liver of diabetic animals thus exerting hypoglycaemic effects by 
increasing hepatic glycogenesis (Gondwe et al., 2008; Mapanga et al., 2009; Ngubane et al., 
2011). Moreover, literature evidence suggests that OA mimics hypoglycaemic effects of 
metformin, a plant-derived biguanide. Metformin has been shown to reduce blood glucose 
concentrations by enhancing insulin sensitivity in peripheral target tissues and suppressing 
hepatic glucose output (Krentz and Bailey, 2005). However, we cannot exclude other blood 
glucose-lowering mechanisms. OA has been reported to have the ability to trigger the effects of 
insulin receptor signaling (Jung et al., 2007). Previous studies have also suggested that the 
hypoglycaemic effects of some triterpernoids such as corosolic, ursolic and myrianthic acid 
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could be due to their insulin mimetic properties (Jung et al., 2007). Therefore, there is a 
possibility that the hypoglycaemic effects of OA in the STZ-induced diabetic rats could be 
attributed to insulin mimetic effects of OA. Interestingly, comparisons of the effects of PI and 
OA-containing dermal patches of different concentrations on blood glucose lowering could not 
be separated statistically. The failure to observe these effects cannot be explained by the present 
study, but may be attributed to the narrow range of the doses used in the present study. These 
effects were also not statistically different from those observed in sc insulin-treated animals. 
 
Glycogen concentrations were measured in the liver and skeletal muscle tissues to establish the 
mechanism used by PI and OA-containing dermal patches to lower blood glucose concentrations. 
Glycogen is the primary storable form of glucose and diabetes mellitus is associated with 
reduced capacity to store glycogen (Chandramohan et al., 2008). Indeed, hepatic and muscle 
glycogen concentrations were significantly reduced in STZ-induced diabetic rats in comparison 
to the non-diabetic rats. These findings were in line with previous studies that reported depletion 
of glycogen concentration in the liver and skeletal muscle of STZ-induced diabetic rats (Vats et 
al., 2003; Denis et al., 2005; Musabayane et al., 2005; Ngubane et al., 2011). Interestingly, 
treatment with PI and OA-containing dermal patches increased hepatic and muscle glycogen 
concentrations of STZ-induced diabetic rats by comparison with respective control. Glycogen 
synthesis in skeletal muscle tissues is dependent on insulin that stimulates translocation of the 
GLUT-4 to the cell membrane to mediate glucose uptake (Saltiel and Kahn, 2001; Wiernsperger, 
2005; Jensen et al., 2006).  We speculate that the stimulating effects of OA-containing dermal 
patches on muscle glycogen in STZ-induced diabetic rats could be perhaps due to insulin 
mimetic properties of OA as muscle glycogen synthesis is dependent on insulin. Furthermore, 
OA-containing dermal patches could also exert hypoglycaemic effects by increasing AMPK 
activity in the STZ-induced diabetic rats, as triterpenoids like glycosides have also been shown 
to increase AMPK activity (Iglesias et al., 2002; Musi et al., 2002; Govers et al., 2004). In the 
liver, glycogen synthesis is via the GLUT-2 transporters (Libal-Weksler et al., 2001; Tana et al., 
2005). Hence there is a possibility that PI and OA-containing dermal patches could have 
increased the expression and activity of the GLUT-2 transporters and glycogen synthase as a 
mechanism of action in increasing glycogen synthesis in the liver. However, the activity of the 
GLUT-2 transporters is non-insulin dependent. Hepatic glycogen concentrations are determined 
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by the extracellular glucose concentrations and glycogenic enzyme activities (Tana et al., 2005). 
Therefore, the increase in glycogen concentrations in STZ-induced diabetic rats by PI and OA-
containing dermal patches is perhaps through various mechanisms which involve increasing the 
activity of the key glycogenic enzymes. 
 
 
This study further investigated the effects of PI containing dermal patches on the expression of 
GLUT-4 and GS in muscle and liver tissues, respectively. Decreased glucose transport activity 
and decreased levels of GLUT-4 have been reported in muscle of diabetic patients (Garvey et al., 
1991; Sinha et al., 1991). Indeed, untreated STZ-induced diabetic rats exhibited decreased levels 
of GLUT-4 and GS in muscle and liver tissues of STZ-induced diabetic rats, respectively. As 
assessed by western blotting, PI treatment significantly increased the expression of GLUT-4 and 
GS of STZ-induced diabetic rats in comparison to untreated STZ-induced diabetic rats. This 
suggests that insulin-containing dermal patches not only improve glycaemic control on STZ-
induced diabetic rats, but also increase glucose utilization and transport in hepatic and skeletal 
muscle tissues, respectively. Interestingly, the effects exerted by PI-containing dermal patch 
were comparable to those of the standard drug. 
 
In summary, the PI and OA-containing dermal patches delivered physiologically relevant 
amounts of pharmacologically active insulin and OA. PI and OA-containing dermal patch 
formulations will be easy to use and will not require elaborative devices to prevent drug leakage 
as in solution formulations. Therefore, the non-invasive dermal patches may offer minimally 














The data of the current study suggest that the pectin hydrogel insulin and OA dermal patches 
have the potential to deliver insulin and OA across the skin and into the blood stream and lowers 
blood glucose concentrations with concomitant alleviation of some symptoms associated with 
diabetes. The findings are of considerable importance because application of insulin- and OA-
containing dermal patches would free diabetic patients from daily bolus injections required to 
maintain physiologically relevant amounts of pharmacologically active insulin. The pectin 
insulin- and OA-containing dermal hydrogel matrix patch would also provide patients with pain-
free self-administration of insulin thereby improving compliance. 
 
5.1. Limitations of the study 
The present study did not elucidate the pharmacokinetics of OA-containing dermal patches as a 
result we cannot make any conclusions on plasma OA concentrations. In addition, this study did 
not evaluate the effects of the novel transdermal formulations on lipid metabolism which is also 
perturbed in cases of diabetes mellitus. The failure to observe a dose-dependent effect of 
different concentrations of PI and OA-containing dermal patches cannot be explained by the 
present study, but may be attributed to the narrow range of the doses used in the present study. 
Further studies with a wider range of insulin and OA doses are expected to provide this 
information. Such data would lead to the development of insulin-containing dermal patches into 
unit dosage forms. Moreover, this study did not assess the effect of transdermally administered 







5.2. Recommendations for future studies                                                                                  
The limitations of the study include the absence of lipid profile and liver function assessment. In 
this regard, it is envisaged to utilize the obese Zucker diabetic rat model in future studies. 
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